

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Design of a randomised, placebo-controlled, double-blind multicentre study assessing the Effect of ColcHicine on the incidence of knee or hip replacements in symptomatic knee or hip Osteoarthritis: the ECHO trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-098096
Article Type:	Protocol
Date Submitted by the Author:	17-Dec-2024
Complete List of Authors:	Heijman, Michelle; Sint Maartenskliniek, Department of Research; Radboud University Medical Center, Department of Rheumatology van den Ende, Cornelia; Sint Maartenskliniek, Department of Research; Radboud University Medical Center, Department of Rheumatology Cornel, Jan; Radboud University Medical Center, Department of Cardiology; Noordwest Ziekenhuisgroep, Department of Cardiology; Dutch Network for Cardiovascular Research (WCN) Smolders, José; Sint Maartenskliniek, Department of Orthopedics Schers, Henk; Radboud University Medical Center, Department of Primary and Community Care Kievit, Wietske; Radboud University Medical Center, Department of Health Evidence Koeter, Sander; Canisius Wilhelmina Hospital, Department of Orthopedics van den Bemt, Bart; Sint Maartenskliniek, Department of Pharmacy; Radboud University Medical Center, Department of Pharmacy; Radboud University Medical Center, Department of Rheumatology; Radboud University Medical Center, Department of Rheumatology; Radboud University Medical Center, Department of Rheumatology;
Keywords:	RHEUMATOLOGY, Hip < ORTHOPAEDIC & TRAUMA SURGERY, Knee < ORTHOPAEDIC & TRAUMA SURGERY, Drug Therapy, Randomized Controlled Trial, Inflammation
	-

SCHOLARONE[™] Manuscripts

BMJ Open

3 4 5	1	Design of a randomised, placebo-controlled, double-blind multicentre study
5 6 7	2	assessing the Effect of ColcHicine on the incidence of knee or hip replacements
8 9 10 11	3	in symptomatic knee or hip Osteoarthritis: the ECHO trial
12 13	4	Michelle W.J. Heijman ^{1,2*} , Cornelia H.M. van den Ende ^{1,2} , Jan H. Cornel ^{3,4,5} , José M.H.
14 15 16	5	Smolders ⁶ , Henk J. Schers ⁷ , Wietske Kievit ⁸ , Sander Koëter ⁹ , Bart J.F. van den Bemt ^{10,11} , Calin
17 18 19	6	D. Popa ^{2,12}
20 21 22	7	¹ Department of Research, Sint Maartenskliniek, Nijmegen, The Netherlands
23 24 25	8	² Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The
26 27	9	Netherlands
28 29 30	10	³ Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands
31 32 33 34	11	⁴ Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
35 36 37	12	⁵ Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands
38 39 40	13	⁶ Department of Orthopedics, Sint Maartenskliniek, Nijmegen, The Netherlands
41 42	14	⁷ Department of Primary and Community care, Radboud University Medical Centre, Nijmegen,
43 44 45	15	The Netherlands
46 47 48	16	⁸ Department of Health Evidence, Radboud University Medical Centre, Nijmegen, The
49 50	17	Netherlands
51 52 53 54	18	⁹ Department of Orthopedics, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
55 56 57	19	¹⁰ Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands
58 59 60	20	¹¹ Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands

2	assessing the Effect of ColcHicine on the incidence of knee or hip replacements
3	in symptomatic knee or hip Osteoarthritis: the ECHO trial
4	Michelle W.J. Heijman ^{1,2*} , Cornelia H.M. van den Ende ^{1,2} , Jan H. Cornel ^{3,4,5} , José M.H.
5	Smolders ⁶ , Henk J. Schers ⁷ , Wietske Kievit ⁸ , Sander Koëter ⁹ , Bart J.F. van den Bemt ^{10,11} , Calin
6	D. Popa ^{2,12}
7	¹ Department of Research, Sint Maartenskliniek, Nijmegen, The Netherlands
8	² Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The
9	Netherlands
10	³ Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands
11	⁴ Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
12	⁵ Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands
13	⁶ Department of Orthopedics, Sint Maartenskliniek, Nijmegen, The Netherlands
14	⁷ Department of Primary and Community care, Radboud University Medical Centre, Nijmegen,
15	The Netherlands
16	⁸ Department of Health Evidence, Radboud University Medical Centre, Nijmegen, The
17	Netherlands
18	⁹ Department of Orthopedics, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
19	¹⁰ Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands

1 2 3 4 5	21	¹² Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
6 7	22	
o 9 10 11	23	*Corresponding author:
12 13 14	24	Michelle Heijman
15 16 17	25	Department of Research
18 19 20	26	Sint Maartenskliniek
21 22 23	27	Hengstdal 3, 6574 NA
24 25 26	28	Ubbergen, The Netherlands
27 28 29	29	Tel: +31243659185
30 31 32 33 34	30	Email: <u>m.heijman@maartenskliniek.nl</u>
35 36 37		
38 39 40		
41 42 43		
44 45		
46 47 48		
49		
50 51		
52 53 54		
55 56		
57 58		
59 60		

31 Abstract

Introduction: Osteoarthritis is a multi-factorial disease in which low-grade inflammation is considered to play a pivotal role. Although colchicine is a widely used anti-inflammatory drug in the treatment of gout, its effect in osteoarthritis is still disputed due to inconsistent results of short-term clinical trials. Therefore, we aim to evaluate the effect of long-term colchicine 0.5mg once daily on the incidence of knee or hip replacements in patients with knee or hip osteoarthritis.

Methods and analysis: The ECHO trial is a prospective, multicentre, randomised, double-blind, placebo-controlled, phase III trial in which 1200 participants with knee or hip osteoarthritis tolerant to colchicine during a 30-day run-in period will be 1:1 randomised to colchicine 0.5 mg once daily or matching placebo using concealed allocation. The primary endpoint is the time from randomisation to the first knee or hip replacement assessed up to 4.5 years. Secondary endpoints include course of pain, physical function, joint space width, low-grade inflammation, quality of life, clinical or radiological onset of OA in a new joint group other than the hip or knee, number of participants using pain medication during the study, onset of new cardiovascular events (i.e. myocardial infarction, ischemia-driven coronary revascularization, ischemic stroke, peripheral artery disease or cardiovascular death), and direct and indirect costs related to treatment and disease burden due to osteoarthritis. Harm-related endpoints include the number of (serious) adverse events, the number of withdrawals due to (serious) adverse events, and changes in laboratory data (i.e. serum creatinine, eGFR, and ALAT) throughout the study. The primary analysis will be performed according to the intention-to-treat principle.

51 Ethics and dissemination: This trial has been approved by the METC East-Netherlands. Findings will be 52 presented at scientific meetings and published in a peer-reviewed scientific journal.

Registration details: CTIS: 2024-511359-16-00. Clinicaltrials.gov: NCT06578182.

54 Strengths and limitations of this study

This is the first randomised controlled trial with low-dose, long-term treatment of colchicine in a large number of patients with osteoarthritis The trial is designed to facilitate the registration of colchicine as repurposed drug for the indication of knee or hip osteoarthritis rte esuits medication may su Participants will be recruited from multiple centres in the Netherlands, improving the _ generalizability of the results Adherence to trial medication may subside over time

62 Introduction

Osteoarthritis is one of the leading causes of pain and disability, currently affecting more than 500 million people worldwide (1). Towards 2050, it is estimated that the number of osteoarthritis patients will rise by 60 to 100% along with increases in the prevalence of obesity and longevity (2). Without any disease-modifying osteoarthritic drugs (DMOADs) available, a substantial challenge to healthcare systems is posed (3).

The pathophysiology of osteoarthritis is multifactorial and a low-grade chronic inflammation, indicative of an inflammatory phenotype, has been described in the affected joints (4,5). This inflammation is mediated primarily by the innate immune system. A critical component of the innate immune system is the NLRP3 inflammasome, which mediates caspase-1 activation and the secretion of proinflammatory cytokine interleukin 1 beta (IL-1 β) (6). IL-1 β is considered one of the major players implicated in the pathogenesis of osteoarthritis, by both activating innervating nociceptors and promoting joint destruction via catabolic proteins such as matrix metalloproteinases (MMPs) (7). This suggests that therapeutically targeting this pathway in OA may potentially prevent or reduce cartilage destruction and pain, thereby slowing the progression of the disease.

An exploratory analysis in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
trial involving patients with a history of myocardial infarction has recently supported this hypothesis
(8). Inhibiting IL-1β with canakinumab reduced the rates of total knee replacements (TKR) and total
hip replacements (THR) during a median follow-up of 3.7 years (hazard ratio, 0.58 [Cl, 0.42 to 0.80])
(9). Due to the high cost of canakinumab, however, further exploration of affordable anti-inflammatory
therapies with similar properties for the treatment of osteoarthritis is warranted.

Colchicine, an alkaloid extracted from the autumn crocus (*Colchicum autumnale*), is effective in many
 inflammatory and fibrotic conditions with an acceptable safety profile (10). By binding to tubulins, it
 prevents microtubules from assemblage and polymerization. This results in disrupted microtubules

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

86 function and broad cellular actions including inhibition of the NLRP3 inflammasome and MMP13 (11).

87 Hence, there is reason to assume that colchicine may slow the progression of osteoarthritis.

Up to now, clinical trials evaluating the effect of colchicine in osteoarthritis have shown inconsistent results. Four randomised controlled trials (with follow-ups of less than 6 months) using colchicine 0.5 mg twice daily alone or in combination with nimesulide or piroxicam versus placebo alone or in combination with nimesulide or piroxicam and one randomised controlled trial using colchicine 1.5 mg once daily in combination with paracetamol versus paracetamol alone demonstrated symptomatic benefits regarding pain, function, and global assessment in patients with osteoarthritis (12–16). Moreover, in a non-randomised controlled trial, administration of colchicine 0.5 mg twice daily in combination with paracetamol resulted in stable levels of cartilage oligomeric matrix protein (COMP), suggesting stability of the cartilage (17). When paracetamol was used alone, the levels of serum COMP significantly increased from two months to one year. The results of this study indicate that colchicine might act as a DMOAD by stabilizing cartilage turnover and preventing further degradation.

In contrast, in the COLchicine effectiveness in symptoms and inflammation modification in Knee OsteoArthritis (COLKOA) study, no statistically significant difference in knee osteoarthritis symptoms was seen between colchicine 0.5 mg twice daily and placebo over 16 weeks (18). Nevertheless, COLKOA did find that colchicine reduced systemic inflammation based on high-sensitivity C-reactive protein (hs-CRP) and bone turnover based on Cross-Linked C-Telopeptide Of Type I Collagen (CTXI) which are both biomarkers that are associated with the progression of osteoarthritis. Furthermore, 0.5 mg twice daily colchicine over three months failed to improve symptoms in patients with osteoarthritis in the hands compared with placebo in two randomised controlled trials, but one of these trials may have been underpowered and was likely diluted by non-inflamed osteoarthritis subjects (19-21). Lastly, comparing the efficacy of 1 mg/day colchicine treatment versus 16 weeks of physical therapy in 62 patients with knee osteoarthritis showed that physical therapy was more effective than colchicine in reducing pain and improving physical function (22).

BMJ Open

Due to these contradictory results, there is currently not enough evidence to recommend colchicine as a treatment for knee or hand osteoarthritis (12,23). However, it is important to note that each study included no more than 150 patients with follow-up periods not exceeding 1 year. To study the long-term effects of colchicine, a post-hoc analysis of the LoDoCo2 trial was recently performed in which 5522 patients with evidence of coronary disease were randomly assigned to receive colchicine 0.5 mg once daily or matching placebo over a median follow-up of 28.6 months (24). Based on the adverse event data, colchicine 0.5 mg daily was associated with a lower incidence of total knee or hip replacements as compared to placebo (hazard ratio, 0.69 [CI, 0.51 to 0.95]) (25). Long-term safety data from this randomised controlled trial did not show an increase in life-threatening or serious AEs (26). Further investigation of long-term therapy with colchicine to slow disease progression in osteoarthritis is needed as the LoDoCo2 trial was not designed for this purpose.

Therefore, we aim to evaluate the effect of long-term use of colchicine 0.5mg once daily compared to
 placebo in patients with knee or hip OA on the incidence of knee or hip replacement throughout 3 to
 124 4.5 years.

125 Methods and analysis

This protocol has been reported following the SPIRIT guidelines (Additional file 1) (27).

2 127 Study design

The ECHO trial is designed as a multicentre, randomised, placebo-controlled, double-blind, eventdriven superiority trial. After signing informed consent, all eligible patients will use colchicine 129 driven superiority trial. After signing informed consent, all eligible patients will use colchicine 130 1dd0.5mg for 30 days. Patients without adverse events, maintaining adherence, and expressing 131 continued willingness to participate after this open-label run-in period will be randomly allocated in a 132 1:1 ratio to colchicine or placebo. Depending on the time of inclusion, the trial duration for each patient 133 will range from 3 to 4.5 years as the inclusion period is planned to last 1.5 years and the study end date 134 is approximately the same for all participants. A flowchart is shown in Figure 1.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

135 Study population

To be eligible to participate in this study, participants must meet all of the following criteria: I) clinical diagnosis of knee or hip osteoarthritis; II) aged between 45 and 80 years; and III) at least 2-year history of complaints due to osteoarthritis in the hip and/or knee or documented radiographic changes typical for advanced knee and/or hip osteoarthritis (Kellgren & Lawrence (K&L) score \geq 2). A potential participant who meets any of the following criteria will be excluded from participation: on a waiting list for primary joint replacement surgery of the hip or knee, irrespective of cause, any absolute contraindication for knee or hip replacement in the future, more than one previous hip or knee replacement, other known medical disease that may affect joints, known generalized pain syndromes such as fibromyalgia, renal impairment as evidenced by serum creatinine >150µmol/l or estimated glomerular filtration rate (eGFR) <50mL/min/1.73m2, liver function impairment as evidenced by serum alanine transferase (ALAT) > 3 ULN (upper limit of normal), blood dyscrasia, high frailty (clinical frailty scale \geq 7) or predicted life expectancy < 5 years, peripheral neuritis, myositis or marked myo-sensitivity to statins, current use of colchicine for another indication, intolerance to colchicine, use of macrolide antibiotics (i.e. clarithromycin, erythromycin, azithromycin), antimycotics (i.e. ketoconazole, itraconazole and voriconazole), protease inhibitors & anti-retroviral drugs (i.e. ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (i.e. verapamil, diltiazem), or immunosuppressant (i.e. cyclosporine), current enrolment in another trial, incapacitated patients, pregnant or breastfeeding female, fertile female participants not taking sufficient anti-conception, or male participants unwilling to use effective contraception during the study to prevent pregnancy.

Re

Recruitment and screening procedures

Potentially eligible patients visiting the Department of Orthopaedics or Rheumatology from the referral and participating centres in the Netherlands will be informed by their physicians (Additional file 2). In addition, general practitioner practices of the primary care Practice-based Research Network

BMJ Open

of Radboudumc Nijmegen, ReumaNederland (a national patient organization and rheumatism
 research funder), and P-AL (Poly-Artrose Lotgenoten; a national patient organization) will disseminate
 information on the study and invite people with knee or hip osteoarthritis to show their interest.

Patients who express their interest will be invited to complete an online questionnaire on a secure website (Castor EDC) to assess elementary eligibility criteria and provide their consent to be contacted by a member of the research team. Individuals who had previously expressed their interest before the study's commencement due to national publicity related to our previously published findings of the LoDoCo2 trial will similarly be approached (25). Those deemed potentially eligible will then undergo further screening by phone and will be asked for their consent to contact their treating physician to confirm the diagnosis, send recent X-rays of hip or knee joints if present, and gather additional eligibility information if needed.

Potentially eligible patients who express their willingness to participate during the phone call will undergo a screening visit at one of the locations of the participating centres in the Netherlands. Following informed consent, blood samples will be collected to assess liver and renal function and all participants will be supplied with open-label colchicine 0.5mg once daily for 30 days (run-in period). Participants will be instructed to commence medication after reviewing laboratory results. If intolerance to colchicine is suspected (e.g. gastro-intestinal upset) patients are instructed to stop therapy immediately and encouraged to re-challenge themselves after five days. If symptoms initially resolve but re-occur when the drug is re-introduced, they will be assumed to be intolerant to colchicine. In addition, if estimated glomerular filtration rate (eGFR) >50mL/min/1.73m2 or serum alanine transferase (ALAT) < 3 ULN (upper limit of normal) at the start of the run-in phase, but <50mL/min/1.73m2 or > 3 at baseline patients will not be randomised.

Patients without adverse events, who maintain adherence, and express a continued willingness to
participate after the run-in period will proceed to the baseline visit. Blood samples will be obtained to

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

assess liver and renal function and an X-ray of the index joint will be taken to assess K&L score andjoint space width if not made in the past six months.

186 Randomisation, blinding and treatment allocation

Eligible patients will be randomised to colchicine 0.5 mg once daily or placebo with an allocation ratio of 1:1. Randomisation will be performed by an independent pharmacist of the Sint Maartenskliniek using block randomisation with variable block sizes of 4, 6, and 8 stratified by centre, K&L score, and index joint. The physician, the participant, and all other staff involved in the trial will be masked to the participant's treatment allocation. Concealed allocation is guaranteed by randomisation software that will assign subjects to treatment groups, matching placebo to colchicine, and strict procedures for blinded and unblinded parties in the drug supply chain. The investigator will unblind the treatment allocation of a subject during the clinical trial only if unblinding is relevant to a subject's safety. In case of unblinding, the investigator can open a physical envelope labelled with the participant's treatment number. This envelope will contain information about the trial medication that was received. Other participants will not be unblinded. To assess the success of blinding, participants will be asked annually to indicate which group they believe they are in.

199 Intervention

Colchicine Tiofarma 500 microgram tablets will be orally administered with water once a day. If a dose is missed, it should be taken later during the day or skipped if noticed after 12 hours. A matching placebo is the comparator. Trial medication will be (temporarily) discontinued if health issues overrule treatment continuation as determined by the clinical site investigator or if one of the following drugs are prescribed for a given period: macrolide antibiotics (clarithromycin, erythromycin, azithromycin), antimycotics (ketoconazole, itraconazole, and voriconazole), protease inhibitors and anti-retroviral drugs (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (verapamil, diltiazem), immunosuppressant (cyclosporine).

⁰ 208 **Study procedures**

BMJ Open

2		
3 4	209	Patients will be asked to complete online questionnaires using an electronic Data Capture application
5 6	210	(Castor EDC) at enrolment, at baseline, and every 3 months after that. Face-to-face contact (either site
7 8	211	or home visits) will take place at enrolment, at baseline, and every year during follow-up. The number
9 10 11	212	of visits depends on the moment of inclusion and ranges between a minimum of 5 and a maximum of
12 13	213	7. Participants who discontinue the trial medication or withdraw from the study for any reason will
14 15	214	continue to be followed for the primary outcome (knee or hip replacement). The study procedures are
16 17 18	215	shown in Table 1.
19 20 21	216	<u>Demographics</u>
22 23	217	Data regarding age, sex, ethnicity, education level, profession, employment, index joint, number and
24 25 26	218	type of affected joints, and duration of complaints will be collected at enrolment.
27 28 29	219	Anthropometrics
30 31	220	Height, weight, and waist circumference will be assessed at baseline. Subsequent measures of weight
32 33	221	and waist circumference will be taken during clinical visits. BMI will be calculated using weight and
34 35 36	222	height.
37 38 39	223	The Older Persons and Informal Caregivers Survey – Short Form (TOPICS-SF)
40 41	224	The TOPICS-SF collects information on morbidity status, functional limitations, emotional well-being,
42 43 44	225	pain experience, cognitive problems, social functioning, and self-perceived health utilizing 22 items
45 46 47	226	and will be assessed at enrolment to calculate a frailty index. Higher scores indicate higher frailty (28).
48		
49		
50 51		
52		
53		
54		
55 56		
57		
58		
59		
60		

Table 1. Study overview.

	Enrolment	Baseline						Fo	low	-up_						С
Timenoint in months	-1	0	3	6	9	12	15	18	21	24	27	30	22		51	C.
Fligibility screening	x	•	9		<u> </u>		10	10		<u> </u>	2,	30	33			
Informed consent	×															
Onen label colchicine	^	>														
Allocation	•	×														
Colchicine or placebo		^														
Sociodemographics																
Δαο	v															
Age	~															
JEX Ethnicity	×															
	x															
Education level	x															
Employment	x															
Protession	x															
Height	x															
Weight	х					Х				Х				х		
Waist circumference	х					Х				Х				х		
Disease characteristics																
Index joint	х															
Affected joints	x															
Duration of complaints	x															
Joint replacement		х	х	х	х	х	х	х	х	х	х	х	х	х	х	
New OA diagnosis						х				х				х		
Comorbidities	x	х				х				х				х		
Cardiovascular events		х				х				х				х		
Questionnaires																
Pain medication			х		х		х		х		х		х		х	
MARS-5		х		х		х		х		х		х		х		
NRS pain		X	x	x	x	x	х	x	х	x	x	x	x	х	х	
WOMAC		x	^	x	~	x	~	x	~	x	^	x	~	x		
TOPICS-SE	Y	Λ		Λ		~		^		^		^		Â		
FO-5D-5I	~	Y		v		v		v		v		v		x		
		X		×		×		×		×		×		Y		
		X		X		X		X		X		X		×		
		X		Х		X		Х		X		х		X		
		X				Х				X				X		
X-ray*		Х														
Blood sampling	X	х				Х										

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Hospital visits are indicated in blue and tele contact moments are indicated in yellow. Since the study end date is approximately the same for all patients and the inclusion period is planned to last 1.5 years, the trial duration for an individual patient ranges between 3 and 4.5 years depending on the time of inclusion. *If not made in the past 6 months

1 2		
2 3 4 5	230	<u>Comorbidities</u>
6 7	231	The following comorbid conditions will be documented at each clinical visit: heart disease (for example
8 9	232	angina, heart attack, or heart failure); high blood pressure; problems caused by a stroke; leg pain when
10 11 12	233	walking due to poor circulation; lung disease (for example asthma, chronic bronchitis, or emphysema);
12 13 14	234	diabetes mellitus; kidney disease; diseases of the nervous system (for example Parkinson's disease or
15 16	235	multiple sclerosis); liver disease; cancer (within the last 5 years); depression; arthritis in your back or
17 18	236	other condition affecting your spine; rheumatoid arthritis or another kind of arthritis in addition to
19 20 21	237	osteoarthritis (29).
22 23 24	238	Joint replacement
25 26	239	Participants will be asked every 3 months about any knee or hip replacement surgery through a
27 28	240	multiple-choice question. In case of an event, source documents will be collected for central
29 30 31	241	adjudication.
32 33 34	242	OA diagnosis
35 36	243	Participants will be asked every 12 months about any new osteoarthritis diagnosis in a joint other than
37 38 30	244	the knee or hip through a yes-no question. In case of an event, source documents will be collected for
40 41 42	245	central adjudication.
43 44	246	<u>Cardiovascular events</u>
45 46 47	247	Participants will be asked every 12 months about any cardiovascular event defined as myocardial
48 49	248	infarction, peripheral artery disease, ischemia-driven coronary revascularization, ischemic stroke, or
50 51	249	cardiovascular death through a multiple-choice question. In case of an event, source documents will
52 53 54	250	be collected for central adjudication.
55 56 57 58 59 60	251	Pain medication
		13

Page 14 of 36

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

252	Participants will be asked every 3 months about any concomitant pain medication used, including
253	prescription and over-the-counter medications.
254	Numeric rating scale (NRS)
255	The NRS will assess pain levels during rest and during movement at baseline and every 3 months after
256	that. The NRS consists of 11 numbers from 0 to 10, where 0 means no pain and 10 represents the most
257	imaginable pain.
258	Western Ontario and McMaster Universities Arthritis Index (WOMAC)
259	The WOMAC is designed to assess pain, stiffness, and physical functioning in patients with knee or hip
260	osteoarthritis utilizing 24 questions and will be assessed at baseline and every 6 months after that (30).
261	Higher scores represent worse outcomes.
262	European Quality of Life 5-Dimensions 5-Level (EQ-5D-5L)
263	The EQ-5D-5L measures quality of life at baseline and every 6 months after that using 5 levels of
264	severity in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (31).
265	iMTA Productivity Cost Questionnaire (iPCQ)
266	The iPCQ will assess loss of productivity due to OA or joint replacement surgery based on patient-
267	reported absences from paid or unpaid labour at baseline and every 6 months after that (32).
268	iMTA Medical Consumption Questionnaire (iMCQ)
269	The iMCQ will assess all relevant healthcare-related costs like outpatient visits to medical specialists,
270	hospitalizations, and paramedic care at baseline and every 6 months after that (33).
271	Medication Adherence Report Scale (MARS-5)
272	The MARS-5 questionnaire will be assessed every 6 months to evaluate adherence to trial medication
273	and consists of five self-reported adherence items about forgetting, changing dosage, stopping,

BMJ Open

2 3 4	274	skipping, and taking less medication. Scores range from 5 to 25, with higher scores indicating better
5 6 7	275	medication adherence (34).
7 8 9	276	<u>Pill count</u>
10 11 12	277	Adherence to trial medication will be evaluated through pill counts once a year.
13 14 15	278	Radiography
16 17 18	279	Radiographic examinations include standard clinical radiographs of the index knee or hip at baseline if
19 20	280	not made in the past 6 months and, in a subgroup of 200 patients who have taken at least 80% of the
21 22	281	study medication for a minimum of 2 years at the end of the study. Joint space width will be assessed
23 24	282	using automated software.
25 26 27 28	283	Blood samples
29 30	284	Blood samples will be drawn at enrolment, at baseline, after 1 year, and at the end of the study to
31 32 33	285	assess inflammation (hs-CRP) and safety (kidney function, liver function, creatinine kinase,
33 34 35	286	erythrocytes, leukocytes, thrombocytes, and, if anaemia is present, vitamin B12).
36 37 38	287	Adverse events
39 40 41	288	Abnormal CK, eGFR, and ALAT values will be registered throughout the study period. The following
42 43	289	adverse events will be systematically assessed once a year: gastrointestinal, infectious,
44 45	290	musculoskeletal and connective tissue disorders, cardiac disorders, and neurological disorders.
46 47 48	291	Study endpoints
49 50 51	292	The primary endpoint of this study is time to first incident knee or hip replacement from randomisation
52 53	293	until the date of first documented knee or hip replacement, date of death, date of loss to follow-up,
54 55 56	294	or study end-date, whichever comes first, assessed up to 4.5 years.
57 58	295	Secondary endpoints include 1) course of pain, 2) course of physical function, 3) course of joint space
59 60	296	width, 4) course of low-grade inflammation, 5) course of quality of life, 6) clinical or radiological onset

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

od samples

verse events

dy endpoints

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

of OA in a new joint group other than the hip or knee, 7) number of participants using pain medication during the study, 8) onset of new cardiovascular events, including myocardial infarction, ischemiadriven coronary revascularization, ischemic stroke, peripheral artery disease or cardiovascular death, and 9) direct and indirect costs related to treatment and disease burden due to osteoarthritis from randomisation until the date of first documented knee or hip replacement, date of death, date of loss to follow-up, or study end-date, whichever comes first, assessed up to 4.5 years.

Harm-related endpoints include 1) the number of (serious) adverse events, 2) the number of
withdrawals due to (serious) adverse events, and 3) changes in laboratory data (i.e. serum creatinine,
eGFR and ALAT) throughout the study.

306 Sample size calculation

This trial is designed to accrue a minimum of 380 primary end-point events for the Cox proportional hazard model to achieve 80% power with an alpha of 0.05 and detect a hazard ratio of 0.75 (based on the exploratory results from the LoDoCo2 trial) (25). To achieve this number of events, the number of required patients varies based on the baseline event rate and the inclusion rate (as with more inclusions at the beginning of the inclusion period, patients will on average have longer follow-up within the planned total study duration of 4.5 years). Therefore, an adaptive design that allows for a blinded re-estimation of the sample size based on the observed number of events and speed of inclusion using the R package BSSRed will be applied (35). The required number of patients and duration of the inclusion period for various scenarios regarding baseline event rate and inclusion rate is shown in Table 2. For all scenarios, the maximum study duration until administrative censoring was set to 4.5 years, with a dropout of 10% at 2 years based on data from the LoDoCo2 trial (26). Scenarios concerning primary event rates were based on a previous study on the proportion of knee or hip replacements after 2 years in a sample of patients consulting an orthopaedic surgeon without indication for replacement (25% event rate) and the estimated proportion of patients consulting their general practitioner receiving hip or knee replacement in 2 years (23% event rate) (36). In addition, we

added a scenario with a conservative estimate (20% event rate). Sample size re-estimation is planned
at the end of the planned inclusion period at 18 months and does not require correction for multiplicity

324 as allocation remains blinded and no between-arm comparisons are performed.

Table 2. Estimation of the sample size and length of the inclusion period for varying inclusion rates (1000, 1200, and 1500)
 per 18 months (the planned inclusion period) and primary event rates (20%, 23%, and 25%) per 2 years.

327	Inclusion rate per	Primary event rate per 2 years							
	18 months	20%	23%	25%					
	1000	1504 in 27 months	1280 in 23 months	1168 in 21 months					
328	1200	1398 in 20 months	1200 in 18 months	1134 in 17 months					
	1500	1334 in 16 months	1166 in 14 months	1084 in 13 months					

330 Statistical analysis

Descriptive statistics will be used to describe the study sample. For normally distributed continuous
 variables, means and standard deviations (SDs) will be calculated. For non-normally distributed
 continuous variables, medians and interquartile ranges (IQRs) will be reported. Categorical or
 dichotomous variables will be summarized using absolute numbers and percentages.

The primary analysis will be performed according to the intention-to-treat principle. Kaplan-Meier curves will be used to depict the time to first knee or hip replacement in the two treatment groups. Hazard ratios of treatment with colchicine versus placebo, with corresponding 95% confidence intervals, will be obtained from Cox proportional hazards regression models with stratification by centre, K&L score, and index joint. Sensitivity analyses will be performed by adding covariates for change in body weight over time and cumulative use of pain medication. All randomised patients will be included in the analyses. In addition, a per-protocol analysis of the primary endpoint will be performed in patients who have taken at least 80% of the study medication for a minimum of 2 years.

For the secondary analyses, linear mixed models or generalized estimating equations with repeated
measures will be used to estimate mean between-group differences and their 95% CIs for continuous
and binary secondary outcomes. Participants will be included as random effect and treatment
allocation as fixed effect factors. Missing data will be handled by the mixed model.

Page 18 of 36

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

> A cost-effectiveness analysis will be carried out alongside the trial comparing colchicine to placebo from a societal perspective. First, the EQ-5D-5L will assess the impact of both strategies on the quality of life, and the utility will be used to derive a QALY estimate for each patient according to the trapezium rule. Second, volumes of OA-related care will be measured at the patient level using the iMCQ, and loss of productivity due to OA or joint replacement surgery will be estimated based on patient-reported absences from paid (or unpaid) labour measured with the iPCQ. To determine the cost prices for each volume of consumption, the standard cost prices from the 'Dutch Guidelines for Cost Analyses' and www.medicijnkosten.nl will be used. For units of care where no standard prices are available real cost prices will be determined based on full cost pricing. Productivity losses will be valued through the friction cost method. Finally, the incremental cost-effectiveness ratio will be calculated by dividing the difference in costs (medical and societal) by the difference in QALYs between the groups. The ICER, indicating the additional cost required to gain one QALY, can be compared to the willingness to pay value. Uncertainty in the ICER will be non-parametrically determined using bootstrap techniques (1000 replications).

No formal statistical testing will be conducted for the harm-related endpoints. AEs and SAEs will be presented as numbers and percentages per intervention arm. The relationship between AEs and SAEs with the trial treatment will be evaluated and numbers and percentages of treatment-related AEs and SAEs will be presented per treatment arm. Deaths, AEs, and SAEs resulting in treatment discontinuation will be reported.

366 Harm-related considerations

367 Except for planned hospitalisations because of knee or hip replacements, the investigator will record
 368 all AEs and SAEs including the date of occurrence, a description of the event and its severity, duration,
 369 and the actions taken. All AEs and SAEs will be followed until they have abated or a stable situation
 370 has been reached. Due to the size and duration of the trial, an independent Data and Safety Monitoring
 371 Committee consisting of one rheumatologist, one clinical epidemiologist, and one pharmacist from the

BMJ Open

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
20	
2/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
40	
50	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

372 Sint Maartenskliniek will blindly review the trial's progress including updated figures on recruitment
373 and safety data biannually and will advise on optimal execution. No interim analysis will be done.

374 Data management

Data will be collected and processed following the General Data Protection Regulation (EU) 2016/679.
Data will be entered in Castor EDC, recorded on eCRF forms, and stored on a department server with
automatic back-ups. Paper-based data will be stored in locked cabinets at each site. Data will be kept
for 25 years.

Subjects will be identified by a study-specific subject number and/or code in the database. Names and other identifying details will not be included in any study data electronic file. The key to the code is safeguarded by principle investigators.

382 Data quality will be promoted by data checks. If missing, questionable, or out-of-range values are
 383 identified, these will be queried and corrected if possible. If this is not possible, questionable or out 384 of-range values will be excluded from analyses.

Monitoring and quality assurance will be established according to the advice of the NFU (Dutch Federation of University Medical Centres (NFU)). A qualified monitor of the Department of Research of the Sint Maartenskliniek will visit all participating centres before trial commencement and annually thereafter to check trial procedures, including data recording, verification of source data, and safety assessments.

390 Patient and public involvement

391 From the pre-application of the grant for this project, 2 patient representatives of the STAP panel (Key
 392 To Active Participation; a hospital-based patient panel of around 50 patient research partners with
 393 rheumatic diseases to support orthopedic and rheumatology research (both clinical and preclinical) at
 394 Radboudumc and Sint Maartenskliniek) actively engaged in this project. During this phase, the
 395 relevance and feasibility of this project were assessed. Suggestions were provided about participant

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

> retention, medication adherence, and the assessment of adverse effects. This resulted in insights about the order of questionnaires and the amount and type of contact with researchers. Information about adverse effects and interaction with other drugs has been added to the patient information form (PIF). Their request to investigate differences between men and women has been incorporated in the statistical analysis.

After grant approval, 2 additional patient representatives agreed to actively participate in this project: 1 member of the national patient organization P-AL and 1 member of the STAP panel. They provided feedback on the PIF and evaluated the feasibility for patients by testing study procedures. During later research phases, patient representatives will be involved by drafting a questionnaire to assess elementary eligibility criteria if patients express their interest to participate following disseminated study information from national publicity related to our previously published finding of the LoDoCo2 trial, ReumaNederland or P-AL and promoting participant retention. In addition, patient representatives will give input about the wording of results from a patient perspective, write lay summaries, and can co-author scientific publications.

410 Ethics and dissemination

The proposed trial has been registered with the EU Clinical Trials Register (2024-511359-16-00) and on clinicaltrials.gov (NCT06578182). The protocol has been approved by METC East-Netherlands. Written informed consent will be obtained from all participants by the treating or research physician (Additional file 3). A separate question in the ICF will ask for permission to store and reuse personal data and samples for further research. Findings will be presented at scientific meetings and published with the full trial protocol in a peer-reviewed scientific journal. Pseudonymized data will be made available on reasonable request.

418 Authors' contributions.

BMJ Open

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
30	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
54	
55	
56	
57	
58	
50	

Conception and design: MH, CE, JC, BB, and CP. Design of the statistical analysis plan: MH, CE, and WK.
Drafting of the present manuscript: MH. Critical revision: CE, JC, JS, HS, WK, SK, BB, and CP. Final
approval: MH, CE, JC, JS, HS, WK, SK, BB, CP. Funding acquisition: MH, CE, JC, JS, HS, WK, SK, BB, and
CP.

423 Funding statement

This study is funded by ReumaNederland, ReumaStichting Sint MaartensKliniek, Sint Maartenskliniek,
and ZonMW (GGG - drug rediscovery round 6, project number: 10140262210012). Tiofarma provided
colchicine and matching placebo at a reduced cost. The funders have no role in the study design;
collection, management, analysis, and interpretation of data; writing of the report; and the decision
to submit the report for publication.

429 **Competing interests statement**

JC received consulting fees from Amgen and Novo Nordisk, participated on a Data Safety Monitoring
Board or Advisory Board in the EDIT-CAS study and BioNTech malaria vaccine program, and has a
leadership or fiduciary role in the executive committee LIBREXIA AF and Chair Event Adjudication
committee REDEFINE/REIMAGINE. JS received consulting fees from Smith & Nephew consultancy. SK
has a leadership or fiduciary role in the Board Dutch Knee Society, President Commission on Quality
Royal Dutch Orthopaedic Society, and is chairman of Department Orthopaedic Surgery CWZ.
Full references

Long H, Liu Q, Yin H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to
 2019: Findings From the Global Burden of Disease Study 2019. Arthritis and Rheumatology.
 2022 Jul 1;74(7):1172–83.

Steinmetz JD, Culbreth GT, Haile LM, et al. Global, regional, and national burden of
 osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global
 Burden of Disease Study 2021. Lancet Rheumatol. 2023 Sep 1;5(9):e508–22.

443 3. Osteoarthritis: A serious disease [Internet]. Osteoarthritis Research Society International.
 444 2016 [cited 2022 Aug 18]. Available from: https://oarsi.org/education/oarsi-resources/oarsi 445 white-paper-oa-serious-disease

2			
3 4 5	446 447	4.	Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42.
6 7 8	448 449	5.	Zhu R, Fang H, Wang J, et al. Inflammation as a therapeutic target for osteoarthritis: A literature review of clinical trials. Clinical Rheumatology. Springer Science and Business Media
9	450		Deutschland GmbH; 2024.
10 11 12	451 452	6.	Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12:580–92.
13 14 15	453 454	7.	Conaghan PG, Cook AD, Hamilton JA, et al. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019;15:355–63.
16 17 18	455 456	8.	Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017 Sep 21;377(12):1119–31.
19 20 21 22	457 458 459	9.	Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: Exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2020;173(7):509–15.
23 24 25 26	460 461	10.	Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50.
20 27 28	462 463	11.	Takeuchi K, Ogawa H, Kuramitsu N, et al. Colchicine protects against cartilage degeneration by inhibiting MMP13 expression via PLC- γ 1 phosphorylation. Osteoarthritis Cartilage.
29 30	464		2021;29:1564–74.
31 32 33	465 466	12.	Singh A, Molina-Garcia P, Hussain S, et al. Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials. Clin Rheumatol.
34 35	467		2022;Epub ahead of print.
36	468	13.	Das SK, Mishra K, Ramakrishnan S, et al. A randomized controlled trial to evaluate the slow-
37 38 39	469 470		acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2002;10(4):247–52.
40	471	14.	Das SK, Ramakrishnan S, Mishra K, et al. A randomized controlled trial to evaluate the slow-
41	472		acting symptom-modifying effects of colchicine in osteoarthritis of the knee: A preliminary
42 43	473		report. Arthritis Care Res (Hoboken). 2002;47(3):280–4.
44	474	15.	Aran S, Malekzadeh S, Seifirad S. A double-blind randomised controlled trial appraising the
45 46	475		symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol.
47	476		2011;29:513–8.
48	477	16.	Frden M. Ediz L. Hız Ö. et al. Effect of Colchicine on Total Antioxidant Capacity. Antioxidant
49 50	478		Enzymes and Oxidative Stress Markers in Patients with Knee Osteoarthritis. Int J Clin Med.
51 52	479		2012;3:377–82.
53	480	17.	Srivastava R, Das SK, Goel G, et al. Does long term colchicine prevent degradation of collagen
54 55	481		fiber network in osteoarthritis? Int J Rheum Dis. 2017;21:114–7.
56	482	18.	Leung YY, Haaland B, Huebner JL, et al. Colchicine lack of effectiveness in symptom and
57	483		inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial.
58 59 60	484		Osteoarthritis Cartilage. 2018;26(5):631–40.

1			
2 3 4 5 6	485 486 487	19.	Davis CR, Ruediger CD, Dyer KA, et al. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage. 2021;29(2):208–14.
7 8 9 10	488 489 490	20.	Døssing A, Henriksen M, Ellegaard K, et al. Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol [Internet]. 2023 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2665991323000656
11 12 13	491 492	21.	Plotz B, Pillinger M, Samuels J. Colchicine and clinical trials for hand osteoarthritis. Vol. 30, Osteoarthritis and Cartilage. W.B. Saunders Ltd; 2022. p. 172–3.
14 15 16	493 494	22.	Cioroianu GO, Florescu A, Mușetescu AE, et al. Colchicine versus Physical Therapy in Knee Osteoarthritis. Life. 2022 Sep 1;12(9).
17 18 19 20 21	495 496 497	23.	Liu W, Wang HC, Su C, et al. The Evaluation of the Efficacy and Safety of Oral Colchicine in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trails. Biomed Res Int. 2022;2022:2381828.
22 23 24 25	498 499 500	24.	Nidorf SM, Fiolet ATL, Eikelboom JW, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46–56.
26 27 28 29 30	501 502 503 504	25.	Heijman MWJ, Fiolet ATL, Mosterd A, et al. Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial. Ann Intern Med [Internet]. 2023 May 30; Available from: http://www.ncbi.nlm.nih.gov/pubmed/37247416
31 32 33	505 506	26.	Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838–47.
35 36 37 38	507 508 509	27.	Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials DEVELOPMENT OF THE SPIRIT 2013 STATEMENT [Internet]. Vol. 158, Ann Intern Med. 2013. Available from: www.annals.org
39 40 41 42	510 511 512	28.	Santoso AMM, Lutomski JE, Hofman CS, et al. Development of a Patient-Reported Outcome Measure for Geriatric Care: The Older Persons and Informal Caregivers Survey Short Form. Value in Health. 2018 Oct 1;21(10):1198–204.
43 44 45 46 47 48	513 514 515 516	29.	Rolfson O, Wissig S, van Maasakkers L, et al. Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group. Arthritis Care Res (Hoboken). 2016 Nov 1;68(11):1631–9.
49 50 51 52 53	517 518 519 520	30.	Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–40.
54 55 56	521 522	31.	Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five- level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20:1727–36.
57 58 59 60	523 524 525	32.	Bouwmans C, Krol M, Severens H, et al. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. Value in Health. 2015 Sep 1;18(6):753–8.

2 3 4	526 527	33.	iMTA Productivity and Health Research Group. Manual iMTA Medical Cost Questionnaire (iMCQ). Rotterdam; 2018.
5 6 7 8 9	528 529 530	34.	Chan AHY, Horne R, Hankins M, et al. The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020 Jul 1;86(7):1281–8.
10 11 12	531 532	35.	Friede T, Pohlmann H, Schmidli H. Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis. Pharm Stat. 2019 May 1;18(3):351–65.
$\begin{array}{c} 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	532 533 534 535 536 537	36.	trials: Methods and an application in multiple sclerosis. Pharm Stat. 2019 May 1;18(3):351–65. Mahler EAM, den Broeder AA, den Broeder N, et al. Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis. Clin Exp Rheumatol. 2019;37(3):414–21.

Figure 1. Flowchart of the study.

17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	



Figure 1. Flowchart of the study

440x285mm (157 x 157 DPI)



3



SPIRIT-Outcomes 2022 Checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items)^a

Section	ltem No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Administrative in	formatio	on		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	-	
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	-	
	2b	All items from the World Health Organization Trial Registration Data Set	-	
Protocol version	3	Date and version identifier	-	
Funding	4	Sources and types of financial, material, and other support	-	
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	-	
	5b	Name and contact information for the trial sponsor	_	
	50	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	20	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	2	
Introduction	•	<i>ii</i>		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	_	
	6b	Explanation for choice of comparators	-	
Objectives	7	Specific objectives or hypotheses	-	

60

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Section	No	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Poportod ^t
Trial design	8	Description of trial design	-	Reported
indi deergii		including type of trial (eg. parallel		
		group, crossover, factorial, single		
		group) allocation ratio and		
		framework (eq. superiority		
		equivalence noninferiority		
		exploratory)		
Methods: Partic	ipants, in	terventions, and outcomes		T
Study setting	9	Description of study settings (eg,	-	
		community clinic, academic		
		hospital) and list of countries		
		where data will be collected.		
		Reference to where list of study		
	40	sites can be obtained		
Eligibility criteria	10	niciusion and exclusion criteria for	-	
		participants. Il applicable,		
		engibility chiefla for study centres		
		the interventione (eq. surgeone		
		nsychotheranists)		
nterventions	11a	Interventions for each group with	-	
		sufficient detail to allow		
		replication, including how and		
		when they will be administered		
		(for specific guidance see TIDieR		
		checklist and guide)		
	11b	Criteria for discontinuing or	-	
		modifying allocated interventions		
		for a given trial participant (eq.	0	
		drug dose change in response to		
		harms, participant request, or		
		improving/worsening disease)		
	11c	Strategies to improve adherence	-	
		to intervention protocols, and any		
		procedures for monitoring		
		adherence (eg, drug tablet return,		
		laboratory tests)		
	11d	Relevant concomitant care and		
		interventions that are permitted or		
		prohibited during the trial		
Outcomes	12	Primary, secondary, and other	-	
		outcomes, including the specific		
		measurement variable (eg,		
		systolic blood pressure), analysis		
		metric (eg, change from baseline,		
		inal value, time to event), method		
		or aggregation (eg, median,		
		proportion), and time point for		
		elipical relevance of chases		
		officeasy and have astronomic		
		emicacy and narm outcomes is		
		suongiy recommended		
	1		I	I



Section	No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item
	12.1		Provide a rationale for the selection of the domain for the trial's primary
	10.0		outcome
	12.2		outcome represents within-participant change, define and justify the minimal important change in
	10.0		Individuals
	12.5		continuous but will be analyzed as categorical (method of aggregation), specify the cutoff values to be used
	12.4	KO,	If outcome assessments will be performed at several time points after randomization, state the time points that will be used for analysis
	12.5		If a composite outcome is used, define all individual components of the composite outcome
Participant timeline	13	Time schedule of enrolment, interventions (including any run- ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	-
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	-
	14.1		Define and justify the target difference between treatment groups (eg, the minimal important difference)
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	2/
Methods: Assi	gnment of	interventions (for controlled trials)	·
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should	-
		be provided in a separate	



Occuon	No	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until	-	Reported
Implementation	16c	interventions are assignedWho will generate the allocationsequence, who will enrolparticipants, and who will assignparticipants to interventions	-	
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	-	
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	-	
Methods: Data o	collection,	, management, and analysis		
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol		
	18a.1		Describe what is known about the responsiveness of the study instruments in a population similar to the study sample	
	18a.2		Describe who will assess the outcome (eg, nurse, parent)	
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	-	



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reporte
Data	19	Plans for data entry, coding,	-	
management		security, and storage, including		
		any related processes to promote		
		data quality (eg, double data		
		entry; range checks for data		
		values). Reference to where		
		details of data management		
		procedures can be found if not in		
		the protocol		
Statiatical	200	Statistical matheda for analysing		
mathada	20a	statistical methods for analysing	-	
methous		primary and secondary outcomes.		
		Reference to where other details		
		of the statistical analysis plan can		
		be found, if not in the protocol		
	20a.1		Describe any planned methods to	
			account for multiplicity in the analysis	
			or interpretation of the primary and	
			secondary outcomes (eg, coprimary	
			outcomes, same outcome assessed	
			at multiple time points, or subgroup	
			analyses of an outcome)	
	20b	Methods for any additional	-	
		analyses (eq. subgroup and		
		adjusted analyses)		
	200	Definition of analysis nonulation		
	200	relating to protocol pop	-	
		aunerence (eg, as randomised		
		analysis), and any statistical		
		methods to handle missing data	<u>ک</u>	
Madle a de Mars 14		(eg, multiple imputation)		
wethoas: Monito	pring			
Data monitoring	21a	Composition of data monitoring	-	
		committee (DMC); summary of its		
		role and reporting structure;		
		statement of whether it is		
		independent from the sponsor		
		and competing interests; and		
		reference to where further details		
		about its charter can be found. if		
		not in the protocol. Alternatively		
		an explanation of why a DMC is		
		not needed		
	21h	Description of any interim	_	
	210	analyses and stanning suidelines	-	
		analyses and stopping guidelines,		
		these interior results		
		these interim results and make		
		the final decision to terminate the		
	L	trial		
Harms	22	Plans for collecting, assessing,	-	
		reporting, and managing solicited		
		and spontaneously reported		
		adverse events and other		
		unintended effects of trial		
		interventions or trial conduct		
	1	1	1	1



Section	No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Reported
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators	-	
		and the sponsor		
Ethics and dis	semination	· · · ·		·
Research ethic	s 24	Plans for seeking research ethics	-	
approval		committee/institutional review board (REC/IRB) approval		
Protocol	25	Plans for communicating	-	
amendments		important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registrics iournals, regulators)		
Consent or	26a	Who will obtain informed consent		
assent		or assent from potential trial participants or authorised surrogates, and how (see Item 32)		
	26b	Additional consent provisions for collection and use of participant data and biological specimens in	-	
		ancillary studies, if applicable		
Comdentiality	21	potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial		
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	2	
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	21	
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	-	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	-	
	31b	Authorship eligibility guidelines and any intended use of professional writers	-	



Section	ltem No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
	31c	Plans, if any, for granting public	-	
		access to the full protocol,		
		participant-level dataset, and		
		statistical code		
Appendices				
Informed	32	Model consent form and other	-	
consent		related documentation given to		
materials		participants and authorised		
		surrogates		
Biological	33	Plans for collection, laboratory	-	
specimens		evaluation, and storage of		
		biological specimens for genetic		
		or molecular analysis in the		
		current trial and for future use in		
		ancillary studies, if applicable	IT (Chandand Drotage) Iterres: Decommendation	
Trials) Statement of	aper for importa	nt clarification on the items. Amendments to the	protocol should be tracked and dated. The SPI	s for interventiona
copyrighted by the	SPIRIT Group u	nder the Creative Commons "Attribution-NonCo	mmercial-NoDerivs 3.0 Unported" license and i	s reproduced with
permission.			·	-
Indicates page nun	nbers and/or ma	anuscript location: to be completed by authors.		

3	
4	
5	
6	
7	
8	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
20	
21	
22	
23	
24	
25	
26	
20	
27 20	
20	
29	
30	
31	
32	
33	
34	
35	
36	
20	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40	
47	
48	
49	
50	
51	
52	
53	
54	
55	
55	
50	
5/	
58	
59	

60

	University hospital	Peripheral hospital	Tertiary hospital
Participating centres		CWZ	Sint Maartenskliniek
		Gelderse Vallei Ede*	Reade*
		Noordwest Ziekenhuisgroep Alkmaar*	
		Rijnstate Ziekenhuis Arnhem*	
Referral centres	Radboudumc	Bernhoven Uden	
expressed their willing	gness to participate bu	t are not yet officially registered as centre	
4

5 6 7

8

9 10

11

12

13 14

15

16

17 18

19

20 21

22 23

24

25

26 27

28 29

30

31

32 33

34

35 36

37 38

58 59 60 Proefpersoneninformatie

Bijlage E: toestemmingsformulier proefpersoon

Behorende bij Het effect van colchicine op het aantal knie- of heupprotheses (ECHO)

- Ik heb de informatiebrief gelezen. Ook kon ik vragen stellen. Mijn vragen zijn goed genoeg beantwoord. Ik had genoeg tijd om te beslissen of ik meedoe.
- Ik weet dat meedoen vrijwillig is. Ook weet ik dat ik op ieder moment kan beslissen om toch niet mee te doen met het onderzoek. Of om ermee te stoppen. Ik hoef dan niet te zeggen waarom ik wil stoppen.
- Ik geef de onderzoeker toestemming om mijn huisarts en/of specialist te laten weten dat ik meedoe aan dit onderzoek.
- Ik geef de onderzoeker toestemming om informatie op te vragen bij mijn huisarts en/of specialist(en) die mij behandelt voor artrose.
- Ik geef de onderzoeker toestemming om mijn huisarts of specialist informatie te geven over onverwachte bevindingen uit het onderzoek die van belang zijn voor mijn gezondheid.
- Ik geef de onderzoekers toestemming om mijn gegevens en lichaamsmateriaal te verzamelen en gebruiken. De onderzoekers doen dit alleen om de onderzoeksvraag van dit onderzoek te beantwoorden. En om het middel te laten registreren.
- Ik weet dat voor de controle van het onderzoek sommige mensen al mijn gegevens kunnen inzien. Die mensen staan in deze informatiebrief. Ik geef deze mensen toestemming om mijn gegevens in te zien voor deze controle.
- Ik weet dat ik niet zwanger mag worden/mijn partner niet zwanger mag maken tijdens het onderzoek en tot 6 na het stoppen met de studiemedicatie.
- De onderzoeker heeft met mij besproken hoe ik het beste voorkom dat ik zwanger word/dat mijn partner zwanger wordt.
- Wilt u in de tabel hieronder ja of nee aankruisen?

Ik geef toestemming om mijn gegevens te bewaren om dit te gebruiken voor ander	Ja 🗆	Nee□
onderzoek, zoals in de informatiebrief staat.		
Ik geef toestemming om mijn (overgebleven) lichaamsmateriaal te bewaren om dit	Ja 🗆	Nee□
te gebruiken voor ander onderzoek, zoals in de informatiebrief staat. Het		
lichaamsmateriaal wordt daarvoor nog 10 jaar bewaard.		
Ik geef toestemming om mij eventueel na dit onderzoek te vragen of ik wil meedoen	Ja 🗆	Nee□
met een vervolgonderzoek.		
Ik geef de onderzoekers toestemming om na het onderzoek te laten weten welke	Ja 🗆	Nee□
behandeling ik heb gehad/ in welke groep ik zat.		

- Ik wil meedoen aan dit onderzoek.

Mijn naam is (proefpersoon):	
Handtekening:	Datum://

Proefpersoneninformatie

Ik verklaar dat ik deze proefpersoon volledig heb geïnformeerd over het genoemde onderzoek.

Wordt er tijdens het onderzoek informatie bekend die die de toestemming van de proefpersoon kan beïnvloeden? Dan laat ik dit op tijd weten aan deze proefpersoon.

 Naam onderzoeker (of diens vertegenwoordiger):.....

 Handtekening:.....
 Datum: __ / __ / __

.... De proefpersoon krijgt een volledige informatiebrief mee, samen met een getekende versie van het toestemmingsformulier.

BMJ Open

Design of a randomised, placebo-controlled, double-blind multicentre study assessing the Effect of ColcHicine on the incidence of knee or hip replacements in symptomatic knee or hip Osteoarthritis: the ECHO trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-098096.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Feb-2025
Complete List of Authors:	Heijman, Michelle; Sint Maartenskliniek, Department of Research; Radboud University Medical Center, Department of Rheumatology van den Ende, Cornelia; Sint Maartenskliniek, Department of Research; Radboud University Medical Center, Department of Rheumatology Cornel, Jan; Radboud University Medical Center, Department of Cardiology; Noordwest Ziekenhuisgroep, Department of Cardiology; Dutch Network for Cardiovascular Research (WCN) Smolders, José; Sint Maartenskliniek, Department of Orthopedics Schers, Henk; Radboud University Medical Center, Department of Primary and Community Care Kievit, Wietske; Radboud University Medical Center, Department of Health Evidence Koeter, Sander; Canisius Wilhelmina Hospital, Department of Orthopedics van den Bemt, Bart; Sint Maartenskliniek, Department of Pharmacy; Radboud University Medical Center, Department of Pharmacy Popa, Calin; Sint Maartenskliniek, Department of Rheumatology; Radboud University Medical Center, Department of Rheumatology
Primary Subject Heading :	Rheumatology
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	RHEUMATOLOGY, Hip < ORTHOPAEDIC & TRAUMA SURGERY, Knee < ORTHOPAEDIC & TRAUMA SURGERY, Drug Therapy, Randomized Controlled Trial, Inflammation



BMJ Open

3 4 5	1	Design of a randomised, placebo-controlled, double-blind multicentre study
5 6 7	2	assessing the Effect of ColcHicine on the incidence of knee or hip replacements
8 9 10 11	3	in symptomatic knee or hip Osteoarthritis: the ECHO trial
12 13	4	Michelle W.J. Heijman ^{1,2*} , Cornelia H.M. van den Ende ^{1,2} , Jan H. Cornel ^{3,4,5} , José M.H.
14 15 16	5	Smolders ⁶ , Henk J. Schers ⁷ , Wietske Kievit ⁸ , Sander Koëter ⁹ , Bart J.F. van den Bemt ^{10,11} , Calin
17 18 19	6	D. Popa ^{2,12}
20 21 22	7	¹ Department of Research, Sint Maartenskliniek, Nijmegen, The Netherlands
23 24 25	8	² Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The
26 27	9	Netherlands
28 29 30	10	³ Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands
31 32 33 34	11	⁴ Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
35 36 37	12	⁵ Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands
38 39 40	13	⁶ Department of Orthopedics, Sint Maartenskliniek, Nijmegen, The Netherlands
41 42	14	⁷ Department of Primary and Community care, Radboud University Medical Centre, Nijmegen,
43 44 45	15	The Netherlands
46 47 48	16	⁸ Department of Health Evidence, Radboud University Medical Centre, Nijmegen, The
49 50	17	Netherlands
51 52 53 54	18	⁹ Department of Orthopedics, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
55 56 57	19	¹⁰ Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands
58 59 60	20	¹¹ Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands

2	assessing the Effect of ColcHicine on the incidence of knee or hip replacements
3	in symptomatic knee or hip Osteoarthritis: the ECHO trial
4	Michelle W.J. Heijman ^{1,2*} , Cornelia H.M. van den Ende ^{1,2} , Jan H. Cornel ^{3,4,5} , José M.H.
5	Smolders ⁶ , Henk J. Schers ⁷ , Wietske Kievit ⁸ , Sander Koëter ⁹ , Bart J.F. van den Bemt ^{10,11} , Calin
6	D. Popa ^{2,12}
7	¹ Department of Research, Sint Maartenskliniek, Nijmegen, The Netherlands
8	² Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The
9	Netherlands
10	³ Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands
11	⁴ Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
12	⁵ Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands
13	⁶ Department of Orthopedics, Sint Maartenskliniek, Nijmegen, The Netherlands
14	⁷ Department of Primary and Community care, Radboud University Medical Centre, Nijmegen,
15	The Netherlands
16	⁸ Department of Health Evidence, Radboud University Medical Centre, Nijmegen, The
17	Netherlands
18	⁹ Department of Orthopedics, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
19	¹⁰ Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands

BMJ Open

1 2 3 4 5	21	¹² Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
6 7	22	
o 9 10 11	23	*Corresponding author:
12 13 14	24	Michelle Heijman
15 16 17	25	Department of Research
18 19 20	26	Sint Maartenskliniek
21 22 23	27	Hengstdal 3, 6574 NA
24 25 26	28	Ubbergen, The Netherlands
27 28 29	29	Tel: +31243659185
30 31 32 33 34	30	Email: <u>m.heijman@maartenskliniek.nl</u>
35 36 37		
38 39 40		
41 42 43		
44 45		
46 47 48		
49		
50 51		
52 53 54		
55 56		
57 58		
59 60		

31 Abstract

Introduction: Osteoarthritis is a multi-factorial disease in which low-grade inflammation is considered to play a pivotal role. Although colchicine is a widely used anti-inflammatory drug in the treatment of gout, its effect in osteoarthritis is still disputed due to inconsistent results of short-term clinical trials. Therefore, we aim to evaluate the effect of long-term colchicine 0.5mg once daily on the incidence of knee or hip replacements in patients with knee or hip osteoarthritis.

Methods and analysis: The ECHO trial is a prospective, multicentre, randomised, double-blind, placebo-controlled, phase III trial in which 1200 participants with knee or hip osteoarthritis tolerant to colchicine during a 30-day run-in period will be 1:1 randomised to colchicine 0.5 mg once daily or matching placebo using concealed allocation. The primary endpoint is the time from randomisation to the first knee or hip replacement assessed up to 4.5 years. Secondary endpoints include course of pain, physical function, joint space narrowing, low-grade inflammation, quality of life, clinical or radiological onset of OA in a new joint group other than present at baseline, number of participants using pain medication during the study, onset of new cardiovascular events (i.e. myocardial infarction, ischemia-driven coronary revascularization, ischemic stroke, peripheral artery disease or cardiovascular death), and direct and indirect costs related to treatment and disease burden due to osteoarthritis. Harm-related endpoints include the number of (serious) adverse events, the number of withdrawals due to (serious) adverse events, and changes in laboratory data (i.e. serum creatinine, eGFR, and ALAT) throughout the study. The primary analysis will be performed according to the intention-to-treat principle.

51 Ethics and dissemination: This trial has been approved by the METC East-Netherlands. Findings will be
 52 presented at scientific meetings and published in a peer-reviewed scientific journal.

Registration details: CTIS: 2024-511359-16-00. Clinicaltrials.gov: NCT06578182.

54 Strengths and limitations of this study

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

This is the first randomised controlled trial with low-dose, long-term treatment of colchicine in a large number of patients with osteoarthritis recruited from multiple centres in the Netherlands The primary endpoint is the time from randomisation until the date of first documented knee or hip replacement, date of death, date of loss to follow-up, or study end-date, whichever comes first assessed up to 4.5 years .t-u The adaptive design of this event-driven trial allows for a blinded re-estimation of the sample size Adherence to trial medication may subside over time

BMJ Open

64 Introduction

Osteoarthritis is one of the leading causes of pain and disability, currently affecting more than 500
million people worldwide [1]. Towards 2050, it is estimated that the number of osteoarthritis patients
will globally rise by 60 to 100% along with increases in the prevalence of obesity and longevity [2].
Without any disease-modifying osteoarthritic drugs (DMOADs) available, a substantial challenge to
healthcare systems is posed [3].

The pathophysiology of osteoarthritis is multifactorial and a low-grade chronic inflammation, indicative of an inflammatory phenotype, has been described in the affected joints [4,5]. This inflammation is mediated primarily by the innate immune system. A critical component of the innate immune system is the NLRP3 inflammasome, which mediates caspase-1 activation and the secretion of proinflammatory cytokine interleukin 1 beta (IL-1 β) [6]. IL-1 β is considered one of the major players implicated in the pathogenesis of osteoarthritis, by both activating innervating nociceptors and promoting joint destruction via catabolic proteins such as matrix metalloproteinases (MMPs) [7]. This suggests that therapeutically targeting this pathway in OA may potentially prevent or reduce cartilage destruction and pain, thereby slowing the progression of the disease.

An exploratory analysis in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
trial involving patients with a history of myocardial infarction has recently supported this hypothesis
[8]. Inhibiting IL-1β with canakinumab reduced the rates of total knee replacements (TKR) and total
hip replacements (THR) during a median follow-up of 3.7 years (hazard ratio, 0.58 [Cl, 0.42 to 0.80])
[9]. Due to the high cost of canakinumab, however, further exploration of affordable anti-inflammatory
therapies with similar properties for the treatment of osteoarthritis is warranted.

Colchicine, an alkaloid extracted from the autumn crocus (*Colchicum autumnale*), has been widely
used in acute crystal-induced inflammation and gout flare prophylaxis [10]. By binding to tubulins, it
prevents microtubules from assemblage and polymerization. This results in disrupted microtubules

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

function and broad cellular actions including inhibition of the NLRP3 inflammasome and MMP13 [11].
Hence, there is also reason to assume that colchicine may slow the progression of osteoarthritis.

Up to now, three randomised controlled trials with follow-ups of less than 6 months using colchicine 0.5 mg twice daily alone or in combination with nimesulide or piroxicam versus placebo alone or in combination with nimesulide or piroxicam demonstrated symptomatic benefits regarding pain, function, and global assessment in patients with osteoarthritis [12–15]. These results were confirmed by another randomised controlled trial using colchicine 1.5 mg once daily in combination with paracetamol versus paracetamol alone [16]. Moreover, in a non-randomised controlled trial, administration of colchicine 0.5 mg twice daily in combination with paracetamol resulted in stable levels of cartilage oligomeric matrix protein (COMP), suggesting stability of the cartilage [17]. When paracetamol was used alone, the levels of serum COMP significantly increased from two months to one year. The results of this study indicate that colchicine might act as a DMOAD by stabilizing cartilage turnover and preventing further degradation.

In contrast, in the COLchicine effectiveness in symptoms and inflammation modification in Knee OsteoArthritis (COLKOA) study, no statistically significant difference in knee osteoarthritis symptoms was seen between colchicine 0.5 mg twice daily and placebo over 16 weeks [18]. Nevertheless, COLKOA did find that colchicine reduced systemic inflammation based on high-sensitivity C-reactive protein (hs-CRP) and bone turnover based on Cross-Linked C-Telopeptide Of Type I Collagen (CTXI) which are both biomarkers that are associated with the progression of osteoarthritis. Furthermore, 0.5 mg twice daily colchicine over three months failed to improve symptoms in patients with osteoarthritis in the hands compared with placebo in two randomised controlled trials, but one of these trials may have been underpowered and was likely diluted by non-inflamed osteoarthritis subjects [19-21]. Lastly, comparing the efficacy of 1 mg/day colchicine treatment versus 16 weeks of physical therapy in 62 patients with knee osteoarthritis showed that physical therapy was more effective than colchicine in reducing pain and improving physical function [22].

BMJ Open

Due to these contradictory results, there is currently not enough evidence to recommend colchicine as a treatment for knee or hand osteoarthritis [12,23]. However, it is important to note that each study included no more than 150 patients with follow-up periods not exceeding 1 year. To study the long-term effects of colchicine, a post-hoc analysis of the LoDoCo2 trial was recently performed in which 5522 patients with evidence of coronary disease were randomly assigned to receive colchicine 0.5 mg once daily or matching placebo over a median follow-up of 28.6 months [24]. Based on the adverse event data, colchicine 0.5 mg daily was associated with a lower incidence of total knee or hip replacements as compared to placebo (hazard ratio, 0.69 [CI, 0.51 to 0.95]) [25]. Long-term safety data from this randomised controlled trial did not show an increase in life-threatening or serious AEs [26]. Further investigation of long-term therapy with colchicine to slow disease progression in osteoarthritis is needed as the LoDoCo2 trial was not designed for this purpose. Therefore, we aim to evaluate the effect of long-term use of colchicine 0.5mg once daily compared to placebo in patients with knee or hip OA on the incidence of knee or hip replacement throughout 3 to

3 126 4.5 years.

5 127 Methods and analysis

128 This protocol has been reported following the SPIRIT guidelines (Additional file 1) [27].

129 Study design

The ECHO trial is designed as a multicentre, randomised, placebo-controlled, double-blind, eventdriven superiority trial. After signing informed consent, all eligible patients will use colchicine 0.5mg once daily for 30 days. Patients without adverse events, maintaining adherence, and expressing continued willingness to participate after this open-label run-in period will be randomly allocated in a 1:1 ratio to colchicine or placebo. Depending on the time of inclusion (planned between January 2025 and July 2026), the trial duration for each patient will range from 3 to 4.5 years, as the study end date **BMJ** Open

is approximately the same for all participants (estimated at April 2029). A flowchart is shown in Figure137

138 Study population

To be eligible to participate in this study, participants must meet all of the following criteria: I) clinical diagnosis of knee or hip osteoarthritis; II) aged between 45 and 80 years; and III) at least 2-year history of complaints due to osteoarthritis in the hip and/or knee or documented radiographic changes typical for advanced knee and/or hip osteoarthritis (Kellgren & Lawrence (K&L) score ≥ 2). A potential participant who meets any of the following criteria will be excluded from participation: on a waiting list for primary joint replacement surgery of the hip or knee, irrespective of cause, any absolute contraindication for knee or hip replacement in the future, more than one previous hip or knee replacement, other known medical disease that may affect joints, known generalized pain syndromes such as fibromyalgia, renal impairment as evidenced by serum creatinine >150µmol/l or estimated glomerular filtration rate (eGFR) <50mL/min/1.73m2, liver function impairment as evidenced by serum alanine transferase (ALAT) > 3 ULN (upper limit of normal), blood dyscrasia, high frailty (clinical frailty scale \geq 7) or predicted life expectancy < 5 years, peripheral neuritis, myositis or marked myo-sensitivity to statins, current use of colchicine for another indication, intolerance to colchicine, use of macrolide antibiotics (i.e. clarithromycin, erythromycin, azithromycin), antimycotics (i.e. ketoconazole, itraconazole and voriconazole), protease inhibitors & anti-retroviral drugs (i.e. ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (i.e. verapamil, diltiazem), or immunosuppressant (i.e. cyclosporine), current enrolment in another trial, incapacitated patients, pregnant or breastfeeding female, fertile female participants not taking sufficient anti-conception, or male participants unwilling to use effective contraception during the study to prevent pregnancy.

159 Recruitment and screening procedures

BMJ Open

Potentially eligible patients visiting the Department of Orthopaedics or Rheumatology from the referral and participating centres in the Netherlands will be informed by their physicians (Additional file 2). In addition, general practitioner practices of the primary care Practice-based Research Network of Radboudumc Nijmegen, ReumaNederland (a national patient organization and rheumatism research funder), and P-AL (Poly-Artrose Lotgenoten; a national patient organization) will disseminate information on the study and invite people with knee or hip osteoarthritis to show their interest.

Patients who express their interest will be invited to complete an online questionnaire on a secure website (Castor EDC) to assess elementary eligibility criteria and provide their consent to be contacted by a member of the research team. Individuals who had previously expressed their interest before the study's commencement due to national publicity related to our previously published findings of the LoDoCo2 trial will similarly be approached [25]. Those deemed potentially eligible will then undergo further screening by phone and will be asked for their consent to contact their treating physician to confirm the diagnosis, send recent X-rays of hip or knee joints if present, and gather additional eligibility information if needed.

Potentially eligible patients who express their willingness to participate during the phone call will undergo a screening visit at one of the locations of the participating centres in the Netherlands. Following informed consent, blood samples will be collected to assess liver and renal function and all participants will be supplied with open-label colchicine 0.5mg once daily for 30 days (run-in period). Participants will be instructed to commence medication after reviewing laboratory results. If intolerance to colchicine is suspected (e.g. gastro-intestinal upset) patients are instructed to stop therapy immediately and encouraged to re-challenge themselves after five days. If symptoms initially resolve but re-occur when the drug is re-introduced, they will be assumed to be intolerant to colchicine. In addition, if estimated glomerular filtration rate (eGFR) >50mL/min/1.73m2 or serum alanine transferase (ALAT) < 3 ULN (upper limit of normal) at the start of the run-in phase, but <50mL/min/1.73m2 or > 3 at baseline patients will not be randomised.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Patients without adverse events, who maintain adherence, and express a continued willingness to participate after the run-in period will proceed to the baseline visit. Blood samples will be obtained to assess liver and renal function and an X-ray of the index joint will be taken to assess K&L score and joint space narrowing if not made in the past six months.

189 Randomisation, blinding and treatment allocation

Eligible patients will be randomised to colchicine 0.5 mg once daily or placebo with an allocation ratio of 1:1. Randomisation will be performed by an independent pharmacist of the Sint Maartenskliniek using block randomisation with variable block sizes of 4 and 6 stratified by centre, K&L score, and index joint. The physician, the participant, and all other staff involved in the trial will be masked to the participant's treatment allocation. Concealed allocation is guaranteed by randomisation software that will assign subjects to treatment groups, matching placebo to colchicine, and strict procedures for blinded and unblinded parties in the drug supply chain. The investigator will unblind the treatment allocation of a subject during the clinical trial only if unblinding is relevant to a subject's safety. In case of unblinding, the investigator can open a physical envelope labelled with the participant's treatment number. This envelope will contain information about the trial medication that was received. Other participants will not be unblinded. To assess the success of blinding, participants will be asked annually to indicate which group they believe they are in.

202 Intervention

Colchicine Tiofarma 500 microgram tablets will be orally administered with water once a day. If a dose
 is missed, it should be taken later during the day or skipped if noticed after 12 hours. A matching
 placebo is the comparator. Trial medication will be (temporarily) discontinued if health issues overrule
 treatment continuation as determined by the clinical site investigator or if one of the following drugs
 are prescribed for a given period: macrolide antibiotics (clarithromycin, erythromycin, azithromycin),
 antimycotics (ketoconazole, itraconazole, and voriconazole), protease inhibitors and anti-retroviral

BMJ Open

2		
2 3 4	209	drugs (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-
5 6	210	arrhythmic drugs (verapamil, diltiazem), immunosuppressant (cyclosporine).
7 8 9	211	Study procedures
10 11 12	212	Patients will be asked to complete online questionnaires using an electronic Data Capture application
13 14	213	(Castor EDC) at enrolment, at baseline, and every 3 months after that. Face-to-face contact will take
15 16	214	place at enrolment, at baseline, and every year during follow-up. The number of visits depends on the
17 18 10	215	moment of inclusion and ranges between a minimum of 5 and a maximum of 7. Participants who
20 21	216	discontinue the trial medication or withdraw from the study for any reason will continue to be followed
22 23	217	for the primary outcome (knee or hip replacement). The study procedures are shown in Additional file
24 25	218	3.
26 27 28 29	219	Demographics
30 31	220	Data regarding age, sex, ethnicity, education level, profession, employment, smoking, alcohol, index
32 33 34	221	joint, number and type of affected joints, and duration of complaints will be collected at enrolment.
35 36 37	222	Anthropometrics
38 39	223	Height, weight, and waist circumference will be assessed at baseline. Subsequent measures of weight
40 41	224	and waist circumference will be taken during clinical visits. BMI will be calculated using weight and
42 43 44	225	height.
45 46 47	226	Comorbidities
48 49 50	227	The following comorbid conditions will be documented at each clinical visit: heart disease (for example
50 51 52	228	angina, heart attack, or heart failure); high blood pressure; problems caused by a stroke; leg pain when
53 54	229	walking due to poor circulation; lung disease (for example asthma, chronic bronchitis, or emphysema);
55 56	230	diabetes mellitus; kidney disease; diseases of the nervous system (for example Parkinson's disease or
57 58 59 60	231	multiple sclerosis); liver disease; cancer (within the last 5 years); depression; arthritis in your back or

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

other condition affecting your spine; rheumatoid arthritis or another kind of arthritis in addition toosteoarthritis [28].

234 Joint replacement

Participants will be asked every 3 months about any knee or hip replacement surgery through a
multiple-choice question. In case of an event, source documents will be collected for central
adjudication.

238 OA diagnosis

Participants will be asked every 12 months about any new osteoarthritis diagnosis in a joint other than
the knee or hip through a yes-no question. In case of an event, source documents will be collected for
central adjudication.

242 <u>Cardiovascular events</u>

Participants will be asked every 12 months about any cardiovascular event defined as myocardial infarction, peripheral artery disease, ischemia-driven coronary revascularization, ischemic stroke, or cardiovascular death through a multiple-choice question. In case of an event, source documents will be collected for central adjudication.

247 Pain medication

248 Participants will be asked every 3 months about any concomitant pain medication used, including 249 prescription and over-the-counter medications.

- 250 <u>Numeric rating scale (NRS)</u>
- The NRS will assess pain levels during rest and during movement at baseline and every 3 months after
 that. The NRS consists of 11 numbers from 0 to 10, where 0 means no pain and 10 represents the most
 imaginable pain.
- 60 254 <u>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</u>

BMJ Open

4	
5	2
6	-
7	_
8	4
9	
10	
11	2
12	
13	
14	2
15	
16	2
17	
10	
10	2
20	
20	
21	2
22	
23	-
24	2
25	
26	_
27	4
28	
29	_
30	4
31	
32	2
33	
34	
35	2
36	
37	
38	2
30	
40	2
40 41	-
41	_
42	4
43	
44	2
45	
46	
47	2
48	
49	
50	2
51	
52	
53	2
54	
55	
56	2
57	_
58	_
50	4
60	
00	

The WOMAC is designed to assess pain, stiffness, and physical functioning in patients with knee or hip
osteoarthritis utilizing 24 questions and will be assessed at baseline and every 6 months after that [29].
Higher scores represent worse outcomes.

- 258 <u>European Quality of Life 5-Dimensions 5-Level (EQ-5D-5L)</u>
- 259 The EQ-5D-5L measures quality of life at baseline and every 6 months after that using 5 levels of
- 260 severity in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [30].
- 261 <u>iMTA Productivity Cost Questionnaire (iPCQ)</u>
- , 262 The iPCQ will assess loss of productivity due to OA or joint replacement surgery based on patient-
- 263 reported absences from paid or unpaid labour at baseline and every 6 months after that [31].

264 <u>iMTA Medical Consumption Questionnaire (iMCQ)</u>

- 265 The iMCQ will assess all relevant healthcare-related costs like outpatient visits to medical specialists,
- 2 266 hospitalizations, and paramedic care at baseline and every 6 months after that [32].
- 5 267 <u>Medication Adherence Report Scale (MARS-5)</u>
- The MARS-5 questionnaire will be assessed every 6 months to evaluate adherence to trial medication
 and consists of five self-reported adherence items about forgetting, changing dosage, stopping,
 skipping, and taking less medication. Scores range from 5 to 25, with higher scores indicating better
- ⁴ 271 medication adherence [33].
- 7 272 <u>Pill count</u>
- ¹⁰ 273 Adherence to trial medication will be evaluated through pill counts once a year.
- 3 274 <u>Radiography</u>
- Radiographic examinations include standard clinical radiographs of the index knee or hip at baseline if
- ¹⁸ 276 not made in the past 6 months and, in a subgroup of 200 patients who have taken at least 80% of the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

study medication for a minimum of 2 years at the end of the study. Joint space narrowing will beassessed using automated software.

279 Blood samples

Blood samples will be drawn at enrolment, at baseline, after 1 year, and at the end of the study to assess inflammation (hs-CRP) and safety (kidney function, liver function, creatinine kinase, erythrocytes, leukocytes, thrombocytes, and, if anaemia is present, vitamin B12).

283 Adverse events

Abnormal CK, eGFR, and ALAT values will be registered throughout the study period. The following adverse events will be systematically assessed once a year: gastrointestinal, infectious, musculoskeletal and connective tissue disorders, cardiac disorders, and neurological disorders.

287 Study endpoints

The primary endpoint of this study is time from randomisation until the date of first documented knee
or hip replacement, date of death, date of loss to follow-up, or study end-date, whichever comes first,
assessed up to 4.5 years.

Secondary endpoints include 1) course of pain, 2) course of physical function, 3) course of joint space narrowing, 4) course of low-grade inflammation, 5) course of quality of life, 6) number of participants with and time to clinical or radiological onset of OA in a new joint group other than present at baseline, 7) number of participants using pain medication during the study, 8) onset of new cardiovascular events, including myocardial infarction, ischemia-driven coronary revascularization, ischemic stroke, peripheral artery disease or cardiovascular death, and 9) direct and indirect costs related to treatment and disease burden due to osteoarthritis from randomisation until the date of first documented knee or hip replacement, date of death, date of loss to follow-up, or study end-date, whichever comes first, assessed up to 4.5 years.

BMJ Open

Harm-related endpoints include 1) the number of (serious) adverse events, 2) the number of withdrawals due to (serious) adverse events, and 3) changes in laboratory data (i.e. serum creatinine, eGFR and ALAT) throughout the study.

Sample size calculation

This trial is designed to accrue a minimum of 380 primary end-point events for the Cox proportional hazard model to achieve 80% power with an alpha of 0.05 and detect a hazard ratio of 0.75 (based on the exploratory results from the LoDoCo2 trial) [25]. To achieve this number of events, the number of required patients varies based on the baseline event rate and the inclusion rate (as with more inclusions at the beginning of the inclusion period, patients will on average have longer follow-up within the planned total study duration of 4.5 years). Therefore, an adaptive design that allows for a blinded re-estimation of the sample size based on the observed number of events and speed of inclusion using the R package BSSRed will be applied [34]. The required number of patients and duration of the inclusion period for various scenarios regarding baseline event rate and inclusion rate is shown in Table 1. For all scenarios, the maximum study duration until administrative censoring was set to 4.5 years, with a dropout of 10% at 2 years based on data from the LoDoCo2 trial [26]. Scenarios concerning primary event rates were based on a previous study on the proportion of knee or hip replacements after 2 years in a sample of patients consulting an orthopaedic surgeon without indication for replacement (25% event rate) and the estimated proportion of patients consulting their general practitioner receiving hip or knee replacement in 2 years (23% event rate) [35]. In addition, we added a scenario with a conservative estimate (20% event rate). Based on these assumptions, 1410 patients will enter the run-in phase and 1200 patients will be randomised. Sample size re-estimation is planned at the end of the planned inclusion period at 18 months and does not require correction for multiplicity as allocation remains blinded and no between-arm comparisons are performed.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Table 1. Estimation of the sample size and length of the inclusion period for varying inclusion rates (1000, 1200, and 1500)
 per 18 months (the planned inclusion period) and primary event rates (20%, 23%, and 25%) per 2 years.

25	Inclusion rate per	Primary event rate per 2 years				
	18 months	20%	23%	25%		
326	1000	1504 in 27 months	1280 in 23 months	1168 in 21 months		
	1200	1398 in 20 months	1200 in 18 months	1134 in 17 months		
	1500	1334 in 16 months	1166 in 14 months	1084 in 13 months		
27						

328 Statistical analysis

Descriptive statistics will be used to describe the study sample. For normally distributed continuous variables, means and standard deviations (SDs) will be calculated. For non-normally distributed continuous variables, medians and interquartile ranges (IQRs) will be reported. Categorical or dichotomous variables will be summarized using absolute numbers and percentages.

The primary analysis will be performed according to the intention-to-treat principle. Kaplan-Meier curves will be used to depict the time to first knee or hip replacement in the two treatment groups. Hazard ratios of treatment with colchicine versus placebo, with corresponding 95% confidence intervals, will be obtained from Cox proportional hazards regression models with stratification by centre, K&L score, and index joint. Sensitivity analyses will be performed by adding covariates for change in body weight over time and cumulative use of pain medication. All randomised patients will be included in the analyses. In addition, a per-protocol analysis of the primary endpoint will be performed in patients who have taken at least 80% of the study medication for a minimum of 2 years.

For the secondary analyses, linear mixed models or generalized estimating equations with repeated measures will be used to estimate mean between-group differences and their 95% CIs for continuous and binary secondary outcomes. Participants will be included as random effect and treatment allocation as fixed effect factors. Missing data will be handled by the mixed model.

55
56
57
58345A cost-effectiveness analysis will be carried out alongside the trial comparing colchicine to placebo57
58
59
60346from a societal perspective. First, the EQ-5D-5L will assess the impact of both strategies on the quality59
60347of life, and the utility will be used to derive a QALY estimate for each patient according to the trapezium

BMJ Open

rule. Second, volumes of OA-related care will be measured at the patient level using the iMCQ, and loss of productivity due to OA or joint replacement surgery will be estimated based on patient-reported absences from paid (or unpaid) labour measured with the iPCQ. To determine the cost prices for each volume of consumption, the standard cost prices from the 'Dutch Guidelines for Cost Analyses' and www.medicijnkosten.nl will be used. For units of care where no standard prices are available real cost prices will be determined based on full cost pricing. Productivity losses will be valued through the friction cost method. Finally, the incremental cost-effectiveness ratio will be calculated by dividing the difference in costs (medical and societal) by the difference in QALYs between the groups. The ICER, indicating the additional cost required to gain one QALY, can be compared to the willingness to pay value. Uncertainty in the ICER will be non-parametrically determined using bootstrap techniques (1000 replications).

No formal statistical testing will be conducted for the harm-related endpoints. AEs and SAEs will be presented as numbers and percentages per intervention arm. The relationship between AEs and SAEs with the trial treatment will be evaluated and numbers and percentages of treatment-related AEs and SAEs will be presented per treatment arm. Deaths, AEs, and SAEs resulting in treatment discontinuation will be reported.

364 Harm-related considerations

Except for planned hospitalisations because of knee or hip replacements, the investigator will record all AEs and SAEs including the date of occurrence, a description of the event and its severity, duration, and the actions taken. All AEs and SAEs will be followed until they have abated or a stable situation has been reached. Due to the size and duration of the trial, an independent Data and Safety Monitoring Committee consisting of one rheumatologist, one clinical epidemiologist, and one pharmacist from the Sint Maartenskliniek will blindly review the trial's progress including updated figures on recruitment and safety data biannually and will advise on optimal execution. No interim analysis will be done.

60 372 Data management

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Data will be collected and processed following the General Data Protection Regulation (EU) 2016/679.
Data will be entered in Castor EDC, recorded on eCRF forms, and stored on a department server with
automatic back-ups. Paper-based data will be stored in locked cabinets at each site. Data will be kept
for 25 years.

Subjects will be identified by a study-specific subject number and/or code in the database. Names and
other identifying details will not be included in any study data electronic file. The key to the code is
safeguarded by principle investigators.

Data quality will be promoted by data checks. If missing, questionable, or out-of-range values are
 identified, these will be queried and corrected if possible. If this is not possible, questionable or out of-range values will be excluded from analyses.

Monitoring and quality assurance will be established according to the advice of the NFU (Dutch Federation of University Medical Centres (NFU)). A qualified monitor of the Department of Research of the Sint Maartenskliniek will visit all participating centres before trial commencement and annually thereafter to check trial procedures, including data recording, verification of source data, and safety assessments.

388 Patient and public involvement

From the pre-application of the grant for this project, 2 patient representatives of the STAP panel (Key To Active Participation; a hospital-based patient panel of around 50 patient research partners with rheumatic diseases to support orthopedic and rheumatology research (both clinical and preclinical) at Radboudumc and Sint Maartenskliniek) actively engaged in this project. During this phase, the relevance and feasibility of this project were assessed. Suggestions were provided about participant retention, medication adherence, and the assessment of adverse effects. This resulted in insights about the order of questionnaires and the amount and type of contact with researchers. Information about adverse effects and interaction with other drugs has been added to the patient information form

BMJ Open

397 (PIF). Their request to investigate differences between men and women has been incorporated in the398 statistical analysis.

After grant approval, 2 additional patient representatives agreed to actively participate in this project: 1 member of the national patient organization P-AL and 1 member of the STAP panel. They provided feedback on the PIF and evaluated the feasibility for patients by testing study procedures. During later research phases, patient representatives will be involved by drafting a questionnaire to assess elementary eligibility criteria if patients express their interest to participate following disseminated study information from national publicity related to our previously published finding of the LoDoCo2 trial, ReumaNederland or P-AL and promoting participant retention. In addition, patient representatives will give input about the wording of results from a patient perspective, write lay summaries, and can co-author scientific publications.

408 Ethics and dissemination

The proposed trial has been registered with the EU Clinical Trials Register (2024-511359-16-00) and on clinicaltrials.gov (NCT06578182). The protocol has been approved by METC East-Netherlands. Written informed consent will be obtained from all participants by the treating or research physician (Additional file 4). A separate question in the ICF will ask for permission to store and reuse personal data and samples for further research. Findings will be presented at scientific meetings and published with the full trial protocol in a peer-reviewed scientific journal. Pseudonymized data will be made available on reasonable request.

416 Authors' contributions.

417 Conception and design: MH, CE, JC, BB, and CP. Design of the statistical analysis plan: MH, CE, and WK.
53
54 418 Drafting of the present manuscript: MH. Critical revision: CE, JC, JS, HS, WK, SK, BB, and CP. Final
55
56 419 approval: MH, CE, JC, JS, HS, WK, SK, BB, CP. Funding acquisition: MH, CE, JC, JS, HS, WK, SK, BB, and
57
58 420 CP. Guarantor: CP.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

421 Funding statement

This study is funded by ReumaNederland, ReumaStichting Sint MaartensKliniek, Sint Maartenskliniek, and ZonMW (GGG - drug rediscovery round 6, project number: 10140262210012). Tiofarma provided colchicine and matching placebo at a reduced cost. The funders have no role in the study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.

427 Competing interests statement

JC received consulting fees from Amgen and Novo Nordisk, participated on a Data Safety Monitoring
Board or Advisory Board in the EDIT-CAS study and BioNTech malaria vaccine program, and has a
leadership or fiduciary role in the executive committee LIBREXIA AF and Chair Event Adjudication
committee REDEFINE/REIMAGINE. JS received consulting fees from Smith & Nephew consultancy. SK
has a leadership or fiduciary role in the Board Dutch Knee Society, President Commission on Quality
Royal Dutch Orthopaedic Society, and is chairman of Department Orthopaedic Surgery CWZ. All other
authors have no competing interest to declare.

435 Full references

- Long H, Liu Q, Yin H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to
 2019: Findings From the Global Burden of Disease Study 2019. Arthritis and Rheumatology.
 2022;74:1172–83.
- 439 2. Steinmetz JD, Culbreth GT, Haile LM, et al. Global, regional, and national burden of
 440 osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global
 441 Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e508–22.
- 49 442 3. Osteoarthritis: A serious disease [Internet]. Osteoarthritis Research Society International.
 443 2016 [cited 2022 Aug 18]. Available from: https://oarsi.org/education/oarsi-resources/oarsi 444 white-paper-oa-serious-disease
- 554454.Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the55446pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42.
- 447 5. Zhu R, Fang H, Wang J, et al. Inflammation as a therapeutic target for osteoarthritis: A
 448 literature review of clinical trials. Clinical Rheumatology. Springer Science and Business Media
 449 Deutschland GmbH; 2024.

2			
3 4 5	450 451	6.	Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12:580–92.
6 7 8	452 453	7.	Conaghan PG, Cook AD, Hamilton JA, et al. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019;15:355–63.
9 10 11	454 455	8.	Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377:1119–31.
12 13 14 15	456 457 458	9.	Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: Exploratory analyses from a randomized, double-blind, placebo- controlled trial. Ann Intern Med. 2020;173:509–15.
16 17 18	459 460	10.	Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50.
19 20 21 22 23	461 462 463	11.	Takeuchi K, Ogawa H, Kuramitsu N, et al. Colchicine protects against cartilage degeneration by inhibiting MMP13 expression via PLC-γ1 phosphorylation. Osteoarthritis Cartilage. 2021;29:1564–74.
24 25 26 27	464 465 466	12.	Singh A, Molina-Garcia P, Hussain S, et al. Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials. Clin Rheumatol. 2022;Epub ahead of print.
28 29 30 31	467 468 469	13.	Das SK, Mishra K, Ramakrishnan S, et al. A randomized controlled trial to evaluate the slow- acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2002;10:247–52.
32 33 34 35	470 471 472	14.	Das SK, Ramakrishnan S, Mishra K, et al. A randomized controlled trial to evaluate the slow- acting symptom-modifying effects of colchicine in osteoarthritis of the knee: A preliminary report. Arthritis Care Res (Hoboken). 2002;47:280–4.
30 37 38 39 40	473 474 475	15.	Aran S, Malekzadeh S, Seifirad S. A double-blind randomised controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol. 2011;29:513–8.
41 42 43 44	476 477 478	16.	Erden M, Ediz L, Hız Ö, et al. Effect of Colchicine on Total Antioxidant Capacity, Antioxidant Enzymes and Oxidative Stress Markers in Patients with Knee Osteoarthritis. Int J Clin Med. 2012;3:377–82.
45 46 47	479 480	17.	Srivastava R, Das SK, Goel G, et al. Does long term colchicine prevent degradation of collagen fiber network in osteoarthritis? Int J Rheum Dis. 2017;21:114–7.
48 49 50 51	481 482 483	18.	Leung YY, Haaland B, Huebner JL, et al. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthritis Cartilage. 2018;26:631–40.
52 53 54 55 56	484 485 486	19.	Davis CR, Ruediger CD, Dyer KA, et al. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage. 2021;29:208–14.
57 58 59 60	487 488 489	20.	Døssing A, Henriksen M, Ellegaard K, et al. Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol [Internet]. 2023 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2665991323000656

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3 4 5	490 491	21.	Plotz B, Pillinger M, Samuels J. Colchicine and clinical trials for hand osteoarthritis. Vol. 30, Osteoarthritis and Cartilage. W.B. Saunders Ltd; 2022. p. 172–3.
6 7 8	492 493	22.	Cioroianu GO, Florescu A, Mușetescu AE, et al. Colchicine versus Physical Therapy in Knee Osteoarthritis. Life. 2022;12.
9 10 11 12 13 14 15 16 17 18 19 20 21 22	494 495 496	23.	Liu W, Wang HC, Su C, et al. The Evaluation of the Efficacy and Safety of Oral Colchicine in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trails. Biomed Res Int. 2022;2022:2381828.
	497 498 499	24.	Nidorf SM, Fiolet ATL, Eikelboom JW, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46–56.
	500 501 502 503	25.	Heijman MWJ, Fiolet ATL, Mosterd A, et al. Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial. Ann Intern Med [Internet]. 2023 May 30; Available from: http://www.ncbi.nlm.nih.gov/pubmed/37247416
23 24 25	504 505	26.	Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383:1838–47.
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	506 507 508	27.	Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials DEVELOPMENT OF THE SPIRIT 2013 STATEMENT [Internet]. Vol. 158, Ann Intern Med. 2013. Available from: www.annals.org
	509 510 511 512	28.	Rolfson O, Wissig S, van Maasakkers L, et al. Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group. Arthritis Care Res (Hoboken). 2016;68:1631–9.
	513 514 515 516	29.	Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–40.
	517 518	30.	Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five- level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20:1727–36.
	519 520 521	31.	Bouwmans C, Krol M, Severens H, et al. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. Value in Health. 2015;18:753–8.
	522 523	32.	iMTA Productivity and Health Research Group. Manual iMTA Medical Cost Questionnaire (iMCQ). Rotterdam; 2018.
	524 525 526	33.	Chan AHY, Horne R, Hankins M, et al. The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020;86:1281–8.
56 57 58 59 60	527 528	34.	Friede T, Pohlmann H, Schmidli H. Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis. Pharm Stat. 2019;18:351–65.

1			
2			
5 4	529	35.	Mahler EAM, den Broeder AA, den Broeder N, et al. Short-term clinical worsening is a clear
5	530		predictor for worsening at 2 years in established knee and hip osteoarthritis. Clin Exp
6	531		Rheumatol. 2019;37:414–21.
7	532		
8 9			
10	E 2 2		
11	222		
12 13			
14			
15			
16			
17			
19			
20			
21 22			
22			
24			
25			
26 27			
28			
29			
30 31			
32			
33			
34 35			
36			
37			
38 39			
40			
41			
42 43			
43 44			
45			
46 47			
47			
49			
50			
51 52			
53			
54			
55 56			
57			
58			
59 60			
00			
			20

for beer teries only





SPIRIT-Outcomes 2022 Checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items)^a

Section	Item	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location
Administrative ir	No. Normatic	on		Reported [®]
Titlo	1	Descriptive title identifying the		
The		study design, population, interventions, and, if applicable, trial acronym		
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	-	
	2b	All items from the World Health Organization Trial Registration Data Set	-	
Protocol version	3	Date and version identifier	-	
Funding	4	Sources and types of financial, material, and other support	-	
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	-	
	5b	Name and contact information for the trial sponsor	-	
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities		
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	2	
Introduction	1	oonningee)		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	-	
	6b	Explanation for choice of comparators	-	
Objectives	7	Specific objectives or hypotheses	-	



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single	-	
		group), allocation ratio, and framework (eg, superiority,		
		equivalence, noninferiority, exploratory)		
Methods: Partici	pants. in	terventions, and outcomes		
Study setting	9	Description of study settings (eq	_	
olddy oolling	Ū	community clinic, academic		
		hospital) and list of countries		
		where data will be collected.		
		Reference to where list of study		
		sites can be obtained		
Eligibility criteria	10	Inclusion and exclusion criteria for	-	
		participants. Il applicable,		
		and individuals who will perform		
		the interventions (eq. surgeons		
		psychotherapists)		
Interventions	11a	Interventions for each group with	-	
		sufficient detail to allow		
		replication, including how and		
		when they will be administered		
		(for specific guidance see TIDieR		
	116	Criteria for disceptinuing or		
	an	modifying allocated interventions	-	
		for a given trial participant (eq	0	
		drug dose change in response to		
		harms, participant request, or	1	
		improving/worsening disease)		
	11c	Strategies to improve adherence	-	
		to intervention protocols, and any		
		procedures for monitoring		
		adherence (eg, drug tablet return,		
	11d	Belovant concomitant care and		
	i iu	interventions that are permitted or		
		prohibited during the trial		
Outcomes	12	Primary, secondary, and other	-	
		outcomes, including the specific		
		measurement variable (eg,		
		systolic blood pressure), analysis		
		metric (eg, change from baseline,		
		tinal value, time to event), method		
		or aggregation (eg, median,		
		Proportion, and time point for each outcome. Evplanation of the		
		clinical relevance of chosen		
		efficacy and harm outcomes is		
		strongly recommended		

SPIRIT-Outcomes 2022 item

change, define and justify the minimal important change in

If the outcome data collected are continuous but will be analyzed as categorical (method of aggregation), specify the cutoff values to be used

If outcome assessments will be performed at several time points after randomization, state the time points that will be used for analysis

If a composite outcome is used, define all individual components of the composite outcome

Define and justify the target

difference between treatment groups (eg, the minimal important difference)

outcome

individuals

Provide a rationale for the selection of the domain for the trial's primary

If the analysis metric for the primary outcome represents within-participant



Location

Reported^b

2
3
Δ
5
5
6
/
8
9
10
11
12
13
1/
14
15
10
17
18
19
20
21
22
23
24
25
25
20
27
28
29
30
31
32
33
34
35
26
20
3/
38
39
40
41
42
43
44
45
46
40
47
48
49
50
51
52
53
54
55
56
57
57
58

1

Section

Participant

Sample size

Recruitment

Allocation:

Sequence

generation

timeline

Item

No.

12.1

12.2

12.3

12.4

12.5

13

14

14.1

15

16a

SPIRIT 2013 Item

Time schedule of enrolment.

interventions (including any runins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)

Estimated number of participants

determined, including clinical and statistical assumptions supporting any sample size calculations

Strategies for achieving adequate participant enrolment to reach

needed to achieve study objectives and how it was

target sample size

Method of generating the

allocation sequence (eg,

assign interventions

computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random

sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or

Methods: Assignment of interventions (for controlled trials)

59	
60	

E				
FOR DOOR ROVI	$\Delta W = ntt n \cdot / / n$	mianan nmi cam	1/0110/200111/01110011	nac vntmi
	CVV OINY IILLD.//DI		i/ sitc/ about/ guiacii	1103.0110111



Section	No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Reporte
Allocation	16b	Mechanism of implementing the	-	
concealment		allocation sequence (eg, central		
mechanism		telephone; sequentially		
		numbered, opaque, sealed		
		envelopes) describing any steps		
		to conceal the sequence until		
		interventions are assigned		
Implomentation	160	Who will gonorate the allocation		
Implementation	100		-	
		sequence, who will enrol		
		participants, and who will assign		
		participants to interventions		
Blinding	170	Who will be blinded after		
(masking)	17a	assignment to interventions (og	-	
(masking)		assignment to interventions (eg,		
		trial participants, care providers,		
		outcome assessors, data		
		analysts), and how		
	17b	If blinded, circumstances under	-	
		which unblinding is permissible,		
		and procedure for revealing a		
		participant's allocated intervention		
		during the trial		
Methods: Data o	collection,	management, and analysis		
Data collection	18a	Plans for assessment and	-	
methods		collection of outcome baseline		
		and other trial data including any		
		related processes to promote data		
		related processes to promote data		
		quality (eg, duplicate		
		measurements, training of		
		assessors) and a description of		
		study instruments (eg,		
		questionnaires, laboratory tests)		
		questionnaires, laboratory tests) along with their reliability and	7	
		questionnaires, laboratory tests) along with their reliability and validity, if known, Reference to	2	
		questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can	2	
		questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	20,	
	18a.1	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the	
	18a.1	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study	
	18a.1	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to	
	18a.1	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample	
	18a.1	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample	
	18a.1 18a.2	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the	
	18a.1 18a.2	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eq. nurse. parent)	
	18a.1 18a.2	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Plans to promote participant retention and complete follow-up,	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Plans to promote participant retention and complete follow-up, including list of any outcome data	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent)	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent) -	
	18a.1 18a.2 18b	questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Describe what is known about the responsiveness of the study instruments in a population similar to the study sample Describe who will assess the outcome (eg, nurse, parent) -	



Section	No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Reported
Data	19	Plans for data entry, coding.	-	Roportet
management		security, and storage, including		
		any related processes to promote		
		data quality (eq. double data		
		data quality (eg, double data		
		entry; range checks for data		
		values). Reference to where		
		details of data management		
		procedures can be found, if not in		
		the protocol		
Statistical	20a	Statistical methods for analysing	-	
methods		primary and secondary outcomes		
		Reference to where other details		
		of the statistical analysis plan can		
		be found if not in the protocol		
	200.1		Describe any planned methods to	
	20a. I		Describe any planned methods to	
			account for multiplicity in the analysis	
			or interpretation of the primary and	
			secondary outcomes (eg, coprimary	
			outcomes, same outcome assessed	
			at multiple time points, or subgroup	
		\sim	analyses of an outcome)	
	20b	Methods for any additional	-	
		analyses (eq. subgroup and		
		adjusted analyses)		
	200	Definition of analysis population	_	
	200	relating to protocol non-		
		adherence (og as rendemined		
		autherefice (eg, as failuoittiseu		
		analysis), and any statistical		
		methods to handle missing data		
Mathada, Manite		(eg, multiple imputation)		
	ning I o t			Т
Data monitoring	21a	Composition of data monitoring	4	
		committee (DIVIC); summary of its		
		role and reporting structure;		
		statement of whether it is		
		independent from the sponsor		
		and competing interests; and		
		reference to where further details		
		about its charter can be found if		
		not in the protocol Alternatively		
		an explanation of why a DMC is		
		an explanation of why a DIVIC is		
	210	Description of any interim	-	
		analyses and stopping guidelines,		
		including who will have access to		
		these interim results and make		
		the final decision to terminate the		
		trial		
Harms	22	Plans for collecting assessing	-	1
		reporting and managing solicited		
		and spontaneously reported		
		and spontaneously reported		
		adverse events and other		
		unintended effects of trial		
		interventions or trial conduct		



Section	No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Reporte
Auditing	23	Frequency and procedures for	-	
		auditing trial conduct, if any, and		
		whether the process will be		
		independent from investigators		
		and the sponsor		
Ethics and disse	mination			
Research ethics	24	Plans for seeking research ethics	-	
approval		committee/institutional review		
		board (REC/IRB) approval		
Protocol	25	Plans for communicating	-	
amendments		important protocol modifications		
		(eg, changes to eligibility criteria,		
		outcomes, analyses) to relevant		
		parties (eg, investigators,		
		REC/IRBs, trial participants, trial		
		registries, journals, regulators)		
Consent or	26a	Who will obtain informed consent	-	
assent		or assent from potential trial		
		participants or authorised		
		surrogates, and how (see Item		
		32)		
	26b	Additional consent provisions for	-	
		collection and use of participant		
		data and biological specimens in		
		ancillary studies, if applicable		
Confidentiality	27	How personal information about		
Connacinality	21	notential and enrolled participants		
		will be collected shared and		
		maintained in order to protect		
		confidentiality before during and	0	
		after the trial		
Declaration of	28	Financial and other competing	-	
interests		interests for principal investigators		
		for the overall trial and each study		
		site		
Access to data	29	Statement of who will have	-	
		access to the final trial dataset,		
		and disclosure of contractual		
		agreements that limit such access		
		for investigators		
Ancillary and	30	Provisions, if any, for ancillary and	-	
post-trial care		post-trial care, and for		
		compensation to those who suffer		
		harm from trial participation		
Dissemination	31a	Plans for investigators and	-	
policy		sponsor to communicate trial		
		results to participants healthcare		
		professionals the public and		
		other relevant groups (eq. via		
		nublication reporting in results		
		databases or other data shering		
		arrangements) including any		
		publication rostrictions		
	246	Authorphin aligibility guidalings		
	310	Authorship eligibility guidelines	-	
		and any intended use of		
	1	protessional writers		



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
	31c	Plans, if any, for granting public	-	
		access to the full protocol,		
		participant-level dataset, and		
		statistical code		
Appendices				
Informed	32	Model consent form and other	-	
consent		related documentation given to		
materials		participants and authorised		
Piologiaal	22	Blans for collection Jaboratory		
specimens	33	evaluation, and storage of	-	
specimens		biological specimens for genetic		
		or molecular analysis in the		
		current trial and for future use in		
		ancillary studies if applicable		
It is strongly recomr	nended that thi	is checklist be read in conjunction with the SPIR	IT (Standard Protocol Items: Recommendation	s for Interventiona

Page 33 of 36

	University hospital	Peripheral hospital	Tertiary hospital													
Participating centres		Canisius Wilhelmina Hospital	Sint Maartensklinie													
		Gelderse Vallei*	Reade*													
		Noordwest Hospital Group Alkmaar*														
		Rijnstate*														
		Reinier Haga Medical Diagnostic Centre*														
Referral centres	Radboudumc	Bernhoven														
*avpraced the	ir willingnoss to partie	inate but are not yet officially registered as con														
		Dasenne	2	6	0 4	12	1 -	10	0w-	up 24-	27	20	22		E 1	CIUSE
-------------------------	----	---------	---	--------	-----	----	-----	--------	-----	-----------	----	----	----	------	------------	---------
Timepoint in months	-1	0	3	6	9 1	12	15	18	21	24	27	30	33	••••	21	36-
Eligibility screening	X															
Informed consent	X															
Open label colchicine																
Allocation		Х														
Colchicine or placebo																
Sociodemographics																
Age	x															
Sex	x															
Ethnicity	x															
Education level	x															
Employment	x															
Profession	x															
Smoking	x															
Alcohol	x															
Height	x															
Weight	x					х				х				х		х
Waist circumference	x					х				х				х		х
Disease characteristics																
Index joint	x															
Affected joints	x															
Duration of complaints	×															
Joint replacement			x	x	x	x	x	x	х	x	x	х	x	х	х	x
New OA diagnosis				~	~	x				x			~	х		x
Comorbidities	×	x				x				x				x		x
Cardiovascular events	A	x				x				x				x		x
Questionnaires		~				^				^				~		^
Dain modication			v		v		v		v		v		v		v	
		v	~	v	^	v	~	v	^	v	X	v	~	y	^	v
NDC nain	V	X	Y	A V	V	×	V	A V	V	×	V	X	V	×	v	X
	X	X	x	X	X	x	X	X	X	X	х	X	X	Ŷ	^	X
		X		X		X		X		X		X		X		Х
		X		X		X		X		X		X		X		X
		X		Х		X		X		X		X		X		х
		Х		X		X		X		Х		Х		X		Х
		Х				Х				Х				Х		Х
X-ray*		Х														Х
Blood sampling	X	Х				Х										х

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

depending on the time of inclusion. *If not made in the past 6 months

Subject Information

Belonging to The effect of colchicine on the number of knee- and hip prostheses (ECF	IO)	
 I have read the information sheet. I was able to ask questions. My questions h been answered well enough. I had enough time to decide if I wanted to take p I know that taking part is voluntary. I also know that at any time I can decide n take part in the study. Or to stop taking part. I do not have to explain why. I give the investigator consent to inform my doctor and/or specialist who treats that I am taking part in this study. 	ave art. ot to s me	
 I give consent to request information from my doctor and/or specialist treating about osteoarthritis. 	me	
 I give consent to give my doctor or specialist information about accidental disc made during the study that are important for my health. I give consent to collect and use my data and/or body material. The investigat do this to answer the question of this study. And to register the medicinal proc 	overies ors only uct.	
 I know that some people will be able to see all of my data to review the study. people are mentioned in this information sheet. I give consent to let them see data for this review. I know that I cannot get pregnant/cannot get my partner pregnant during the s and until 6 months after stopping the trial medication. 	These my tudy	c
 The investigator discussed with me how I can best prevent becoming pregnan partner from becoming pregnant. 	ıt/my	
 Please tick yes or no in the table below. I give consent to store my data to use for other research, as stated in the 	Yes 🗆	No□
I give consent to have my (remaining) body material stored for use in other research, as stated in the information sheet. The body material is stored for this purpose for another 10 years.	Yes 🗆	No 🗆 🧐
I give consent to ask me after this study if I want to participate in a follow-up study.	Yes 🗆	No⊡ ⁶
I give consent to let me know after the study which treatment I received/in which group I was.	Yes 🗆	No□
- I want to take part in this study.		
		(

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

I declare that I have fully informed this subject about the study mentioned.

If any information becomes known during the study that could influence the subject's consent, I will let this subject know in good time.

Investigator name (or their representative): Date: / / Signature:....

erer The study subject will receive a complete information sheet, together with a signed version of the consent form.